 
Document Type:  Study protocol  
Official Title:  Multicenter, randomized, placebo controlled, double -blind, parallel 
group, dose -finding Phase  [ADDRESS_1239120] N umber:  NCT0430453 4 
Document D ate: 22-Oct-2019 
 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  1of 78
Title Page
Protocol Title: 
Multicenter, r andomized, placebo controlled, double -blind, parallel group, dose -finding Phase 
2study  to evaluate the eff icacy  and safety  of BAY 2433334 in patients following an acute 
myocardial infarction
Protocol Number: [ZIP_CODE]
Amendment Number: not applicable
Compound Number: BAY 2433334
Study Phase: Phase 2b
Short Title: Phase 2 P rogram of AntiCoagulation via Inhibition of F XIa by 
[CONTACT_50906] C ompound BAY 2433334 – A cute M yocardial
Infarction study
Acronym: PACIFIC -AMI
Sponsor Name [CONTACT_29560]:Non-US: Bay er AG, [ZIP_CODE] L everkusen, [LOCATION_013] 
US territory : Bay er HealthCare Pharmaceuticals Inc., [ADDRESS_1239121], [PO_BOX], 
Whippany  NJ [ZIP_CODE]- 0915, [LOCATION_003]
Regulatory Agency Identifier Number(s):IND:[ADDRESS_1239122]: 2019-003244-79
Approval Date: 22OCT 2019
Confidential
The information provided in this document is strictly confidential and is intended solely for the performance of 
the clinical investigation.  Reproduction or disclosure of this document, whether in part or in full, to parties not associated with the clinical investigation or its use for any other purpose w ithout the prior written consent of the 
sponsor is not permitted. 
Throughout this document, symbols indicating proprietary names (®, TM) may not be displayed. Hence, the 
appearance of product names withou t these symbols does not imply that these names are not protected.
CONFIDENTIAL 
Sponsor Signatory 
  
 Clinical Study Protocol 
No. BAY 2433334 / [ZIP_CODE] 
Version 1.0 
Date Page: 2 of78 
Medical Monitor (Study Medical Expert) name [CONTACT_3669] [CONTACT_55861] (TMF). 
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  3of 78
Table of Contents
Title Page ................................................................................................................................... 1
Sponsor Signatory .................................................................................................................... 2
Table of Tables ......................................................................................................................... 6
Table of Figures........................................................................................................................ 61.Protocol Summary ............................................................................................................ 7
1.1 Synopsis ........................................................................................................................... 7
1.2 Schema ........................................................................................................................... 10
1.3 Schedule of Activities (SoA) ......................................................................................... 11
2. Introduction ..................................................................................................................... 13
2.1 Study  Rationale .............................................................................................................. 14
2.2 Background .................................................................................................................... 14
2.2.1 Disease Back ground ................................................................................................... 14
2.2.2 Treatment Guidelines ................................................................................................. 15
2.2.3 FXIa Inhibitor: Mode of Action ................................................................................. 15
2.2.4 BAY 2433334 ............................................................................................................. 16
[IP_ADDRESS] Preclinical / Toxicology  Data .................................................................................. 16
[IP_ADDRESS] Clinical Data............................................................................................................ 162.3 Benefit/Risk Assessment ............................................................................................... 18
3.Objectives and Endpoints ............................................................................................... 20
4.Study Design .................................................................................................................... 22
4.1 Overall Design ............................................................................................................... 22
4.2 Scientific Rationale for Study  Design ........................................................................... 23
4.3 Justification for Dose ..................................................................................................... 24
4.4 End of Study  Definition ................................................................................................. 25
5.Study Population ............................................................................................................. 25
5.1 Inclusion Criteria ........................................................................................................... 25
5.2 Exclusion Criteria .......................................................................................................... 26
5.3 Lifesty le Considerations ................................................................................................ 27
5.4 Screen Failures ............................................................................................................... 27
6.Study Intervention .......................................................................................................... 28
6.1 Study  Intervention(s) Administered ............................................................................... 28
6.2 Preparation/Handling/Storage/Accountability ............................................................... 29
6.3 Measures to Minimize Bias: Randomization and Blinding ........................................... [ADDRESS_1239123]  non- cardiac surgery  or non -
cardiac percutaneous/endoscopic procedures ............................................................. 33
6.5.4 Guidance for man agement of participants who experience a suspected ischemic 
stroke  during the study .............................................................................................. 33
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  4of 78
6.5.5 Guidance for management of participants who experience a suspected new, acute 
recurrent cardiac ischemic event during the stud y ..................................................... 34
6.5.6 Guidance for management of participants who undergo elective coronary  
angiograph y, PCI, or CABG during the stud y ........................................................... 34
6.6 Dose Modification ......................................................................................................... 34
6.7 Interven tion after the End of the Study .......................................................................... 35
7. Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal .......................................................................................... 35
7.1 Discontinuation of Study I ntervention ........................................................................... 35
7.1.1 Temporary  Discontinuation ........................................................................................ 37
7.2 Participant Discontinuation/Withdrawal from the Study ............................................... [ADDRESS_1239124] to Follow Up .......................................................................................................... 37
8.Study Assessments and Procedures ............................................................................... 38
8.1 Efficacy  Assessments .................................................................................................... 38
8.1.1 Primary  Efficacy  Endpoint ......................................................................................... 38
[IP_ADDRESS] Cardiovascular Death .............................................................................................. 39
[IP_ADDRESS] Myocardial Infarction .............................................................................................. 39
[IP_ADDRESS] Stroke ...................................................................................................................... 39
[IP_ADDRESS] Stent Thrombosis..................................................................................................... 408.1.2 Secondary  Efficacy  Endpoint ..................................................................................... 40
8.2 Safety  Assessments ........................................................................................................ 40
8.2.1 Prim ary and Secondary  Safet y Endpoints .................................................................. 40
[IP_ADDRESS] BARC Bleeding Definition ..................................................................................... 41
8.2.2 Exploratory  Safet y Endpoints ..................................................................................... 42
[IP_ADDRESS] TIMI Bleeding Definition ....................................................................................... 42
[IP_ADDRESS] ISTH Major Bleeding .............................................................................................. 43
[IP_ADDRESS] ISTH Clinicall y Relevant Non- Major Bleeding ...................................................... [ADDRESS_1239125] .............................................................................. 478.4 Treatment of Overdose .................................................................................................. 47
8.5 Pharmacokinetics ........................................................................................................... 47
8.6 Pharmacody namics ........................................................................................................ 48
8.7 Genetics ......................................................................................................................... 49
8.8 Biomarkers ..................................................................................................................... 49
8.9 Immunogenicit yAssessment ......................................................................................... 50
8.10 Health Economics/Medical Resource Utilization and Health Economics ..................... 50
9. Statistical Considerations ............................................................................................... 50
9.1 Statistical Hy potheses .................................................................................................... 50
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  5of 78
9.2 Sample Size Determination ........................................................................................... 50
9.3 Populations for Analy ses............................................................................................... 50
9.4 Statistical Analy ses........................................................................................................ 51
9.4.1 Gerenal considerations ............................................................................................... 51
9.4.2 Primary  endpoints ....................................................................................................... 52
9.4.3 Secondary endpoints ................................................................................................... 52
9.4.4 Tertiary /exploratory  endpoints ................................................................................... 53
9.4.5 Other Safet y Anal yses................................................................................................ 53
9.4.6 Other Anal yses........................................................................................................... 53
9.5 Interim Anal yses............................................................................................................ 53
9.6 Independent Data Monitoring Committee (IDMC) ....................................................... 54
10. Supporting Documentation and Operational Considerations .................................... 55
10.1 Appendix 1: Regulatory , Ethical, and Study  Oversight Considerations ........................ 55
10.1.1 Regulatory  and Ethi cal Considerations ...................................................................... 55
10.1.2 Financial Disclosure ................................................................................................... 55
10.1.3 Informed Consent Process .......................................................................................... 55
10.1.4 Data Protection ........................................................................................................... 56
10.1.5 Committees Structure ................................................................................................. 56
[IP_ADDRESS] Executive Committee .............................................................................................. 56
[IP_ADDRESS] Steering Committee (SC) ........................................................................................ 56
[IP_ADDRESS] Independent Data Monitoring Committee (IDMC) ................................................ 57
[IP_ADDRESS] Clinical Events Committee (CEC) .......................................................................... 57
10.1.6 Dissemination of Clinical Study  Data ........................................................................ 57
10.1.7 Data Qualit y Assurance .............................................................................................. 58
[IP_ADDRESS] Data Recording ........................................................................................................ 58
[IP_ADDRESS] Monitoring ............................................................................................................... 59
[IP_ADDRESS] Data processing ....................................................................................................... 60
[IP_ADDRESS] Missing data ............................................................................................................ 60
[IP_ADDRESS] Audit and inspection ................................................................................................ 60
[IP_ADDRESS] Archiving ................................................................................................................. 61
10.1.8 Source Documents ...................................................................................................... 61
10.1.9 Study  and Site Start and  Closure ............................................................................... 61
10.1.10 Publication Policy ....................................................................................................... 62
10.2 Appendix 2: Clinical L aboratory  Tests .......................................................................... 62
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, Evaluating, 
Follow -up, and Reporting .............................................................................................. 64
10.3.1 Definition of AE ......................................................................................................... 64
10.3.2 Definition of SAE ....................................................................................................... 65
10.3.3 Recording and Follow-Up of AE and/or SAE............................................................ 66
10.3.4 Reporting of SAEs ...................................................................................................... 68
10.3.5 Outcome Event Reporting Process Overview ............................................................ 69
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy  Information ......... 69
10.5 Appendix 5: L iver Safet y: Sugge sted Actions and Follow -up Assessments ................. 71
10.6 Appendix 6: Calculating the Child -Pugh score ............................................................. 72
10.7 Appendix 7: Calculating glomerular filtration rate........................................................ 7210.8 Appendix 8: Outcome Events: Data Collection............................................................. 7310.9 Appendix 9: Abbreviations............................................................................................ 74
11.References ........................................................................................................................ 78
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
                     Version 1.0                                                           Page:  6of 78
Table of Tables
Table 1–1 PK, PD and Biomarker Sampling ........................................................................... 13
Table 3–1 Objectives and Endpoints ........................................................................................ 21
Table 4–1 BAY 2433334: dose selection ................................................................................. 24
Table 6–1 Study  interventions.................................................................................................. 29
Table 10–1: Protocol -Required Safet y Laboratory Assessments ............................................. 63
Table 10–2 Liver function monitoring ..................................................................................... 71
Table 10–3 Grading of severit y of liver disease ....................................................................... 72
Table 10–4 Child -Pugh score ................................................................................................... 72
Table of Figur es
Figure 1 –1 Study  design overview........................................................................................... 10
Figure 2 –[ADDRESS_1239126] activation ................................................................................................. 15
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
                     Version 1.0                                                           Page:  7of 78
1. Protocol Summary
1.1 Synopsis
Protocol Title:           Multicenter, randomized, placebo controlled, double -blind, parallel 
group, dose -finding Phase 2study  to evaluate the efficacy  and safet y of 
BAY 2433334 in patients following an acute myocardial infarction .
Short Title: PACIFIC -AMI -Phase 2 P rogram of AntiCoagulation via Inhibition 
of FXIa by [CONTACT_50906] C ompound BAY 2433334 – Acute M yocardial
Infarction study
Rationale: This study  will explore a dose range of BAY 2433334 in order to 
determine the dose that is efficacious and safe and that can be used in a 
Phase 3 study  in the same indication. Rivaroxaban in addition to single 
or dual antiplatelet therapy  (acetylsalicy lic acid +/-clopi[INVESTIGATOR_7745]) is the 
only non- Vitamin K oral anticoagulants ( NOAC )approved for 
secondary  prevention of acute co ronar y syndrome ( ACS )in Europe. In 
addition, the COMPASS study  has also shown the benefit of this 
combination (rivaroxaban in addition to acety lsalicy lic acid) in patients 
with stable coronary  artery  disease (CAD)/peripheral artery  disease 
(PAD). The clinical use of antiplatelet therapi[INVESTIGATOR_885716]. The inhibition of FXIa on top of antiplatelet 
therap yis expected to not lead to a relevant increase in bleeding and 
especiall y major bleeding, while maintaining the efficacy benefit 
shown for the combination of antiplatelet therapi[INVESTIGATOR_885717] .
Objectives and Endpoints:
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  8of 78
Objectives Endpoints
Primary
to evaluate whether the oral FXIa 
inhibitor BAY 2433334 compared to placebo leads to a lower incidence of 
cardiovascular ( CV)death, MI, stroke 
and stent thrombosis in participants with
an acute myocardial infarction and who 
aretreated withdual antiplatelet therapyPrimary Efficacy Endpoint
the composite ofCV death, MI, stroke
and stent thrombosis 
Secondary Efficacy Endpoints
all cause mortality
CV death
MI
stroke
stent thrombosis
to evaluate whether the incidence of 
bleeding is similar for BAY 2433334 
compared to placebo in participants 
withan acute myocardial infarction and 
who are treated withdual antiplatelet 
therapyPrimary Safety Endpoint
Bleeding Academic Research 
Consortium (BARC) definition type 2, 3 
and 5 
Secondary Safety Endpoints
all bleeding
BARC bleeding definition type 3, 5
BARC bleeding definition type 1, 2, 3, [ADDRESS_1239127] ratio of the composite of CV death, MI, stroke  
and stent thrombosis comparing BAY 2433334 (20 and 50 mg pooled) with placebo in adult 
participants with an AMI treated with DAPT while alive and regardless of treatment 
discontinuation.
The secondary  efficacy  estimand saredefined following the same approach for the 
individual secondary  endpoints as done for the primary  efficacy estimand.
The primary  safet y estimand is the hazard ratio of BARC type 2, [ADDRESS_1239128] one dose of study  medication of BAY 2433334 or 
placeb o and while the patient is alive and exposed to study  drug
The secondary  safet y estimands aredefined following the same approach for the individual 
secondary  endpoints as done for the primary  safety  estimand.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  9of 78
Overall Design:
Study  [ZIP_CODE] is a multicenter, randomized, placebo controlled, double -blind, parallel group, 
dose-finding study . 
The study  population includes participants following an AMI with a plan for treatment with 
DAPT (acety lsalicy lic acid + P2Y 12inhibitor) after discha rge from hospi[INVESTIGATOR_307]. 
Participants will be screened and have to be randomized within 5 day s of hospi[INVESTIGATOR_885718].
Stratification will be based on the intended P2Y 12inhibitor use ( ticagrelor/ prasugrel versus 
clopi[INVESTIGATOR_7745]) after hospi[INVESTIGATOR_2345] . 
Participants should have the initial coronary  angiography  and reva scularization procedures, 
either percutaneous coronary  intervention (PCI) or coronary  artery  by[CONTACT_103441](CABG) ,
as treatment for the index AMI  event performe d before randomiz ation . However, a planned ,
staged PCI procedure can be performed after randomization. 
Ifall information is available, participants can be randomized on the day  of screening.
Disclosure Statement: This is aparallel -group study  with 4 arms that is participant and 
investigator blinded
Intervention Model: Parallel
Primary Purpose: Treatment
Number of Arms: 4arms (3 investigational drug arms and 1 placebo arm)
Number of Participants:
Approximately  1650 participants will be screened to achi eve 1600 randomly  assigned to study  
intervention for an estimated total of 400 evaluable participants per intervention group. More 
details are available in Section 9.2 Sample Size Determination.
Intervention Groups and Duration:
BAY 2433334 is the sponsor’s study  intervention under investigation. Placebo is used as 
comparator. Study  intervention duration an d dose regimen are tabulated as follows:
Study PeriodDuration*Dose and FrequencyRoute of
administration
Screening ≤5days
Oral Intervention 26-52 weeks *BAY 2433334 10 mg once daily
BAY 2433334 20 mg once daily
BAY 2433334 50 mg once daily
Placebo once daily
Safety f ollow -up 2 weeks
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  10of 78
Total planned 
number of patientsTotal planned study duration
1600 Between 28 and 54weeks
*The Study  Treatment End Date will be [ADDRESS_1239129] a total treatment duration of a 
minimum 26 weeks to a maximum of 52 weeks.
Data Monitoring Committee: Yes
1.2 Schema
Figure 1–1Study design overview
EOT= End of Treatment, OD=Once Daily, RND=Randomization , N = total number of participant s, W = week

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  11of 78
1.3 Schedule of Activities (SoA)
Study periods /
(Duration)Screening
(SCR) *Intervention period
(26-52weeks ,from RNDuntil End of Treatment visit [EOT ])Early 
terminat
ion
(ET)Safety     
Follow-up
(SFU)
(14 days after 
EOT or ET )
Visit number 1 2 3 4f5 6 7 8 9 10 11 12 12a 13
Visit type site Site  site site site site site site (site)
Week [W]
Study day and allowed 
deviationsSCR
-51RND  / W0
1W2
15±4W4
29±4W8
57±
4W13
92±4W20
141±
4W26
183±
4W32
225±
4W39
274±4W46
323±
4W52/ EOT
365±4  Any 
time
ET+7EOTor 
ETc+2 weeks
379+ [ADDRESS_1239130] X
Inclusion and exclusion criteria X Xa
Demographics and biometrics X
Medical history X
Prior and Concomitant 
medicationX XaXiX XiX XiXXi
X X X X X
Clinical procedures  / assessment s
12-lead ECGdX XaX X X
Vital signs (BP and HR) X XaX X X X X X
Adverse events ============================ Conti nuously========================================= 
Outcome eventsh============================ Conti nuously========================================= 
IxRS
Randomization / Visit 
registration via IxRSX X X X X X X
Laboratory  assessments
Safety blood sample XeXa,eX X X X X X
Pharmacokinetic samplegX X X
Pharmacodynamic samplinggX X X X
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0 Page:  12of 78
Study periods /
(Duration)Screening
(SCR) *Intervention period
(26-52weeks ,from RNDuntil End of Treatment visit [EOT ])Early 
terminat
ion
(ET)Safety     
Follow-up
(SFU)
(14 days after 
EOT or ET )
Visit number 1 2 3 4h5 6 7 8 9 10 11 12 12a 13
Visit ty pe site Site  site site site site  site site (site)
Week [W]
Study day and allowed 
deviationsSCR
-51RND / W0
1W2
15±4W4
29±4W8
57±4W13
92±4W20
141±4W26
183±4W32
225±4W39
274±4W46
323±4W52/ EoTc
365±4 Any time
ET+7EoTor 
ETc+2 weeks
379+[ADDRESS_1239131] inggX X X
Study  drugjadministratio n
Study drugj dispensation XbX X X
Study drugjintake at the sitegX X X no intake
Study drugj
collection and accountabilityXXX X X
Abbreviations: BP= blood pressure, CRF = case report form , ECG = electrocardiogram, EoT = end of treatment, ET = early termination, HR  = 
 heart rate, IxRS = Interactive Voice/ Web Response System, MI = m yocardial infarction PD = pharmacodynamic(s), PK = pharmacokinetic(s), 
RND= ra ndomization, SCR = screening, SFU   =  safety follow -up, SoA = Schedule of Activities, TIA = transient isch emic attack
** Screening andrandomization must occ urduring hospi[INVESTIGATOR_885719] 5 days of hospi[INVESTIGATOR_063] . Intake of the firstdose of study 
drug will start as soon as possible and on the same day as randomization (day 1).
aifscreening and randomization are performed on the same day, this procedure does not need to be repeated.
bat each contact, participants should be reminded regarding study drug compliance .
cParticipants will perform their safety follow -up phone call 2 weeks after the EoT visit or the ET visit whichever occurs earlier .(i.e. in case of Early 
Termina tion [ADDRESS_1239132] study drug intake ).
dECG machine that automatically calculates the heart rate and measures PR, QRS, QT and QTc intervals should be used.
eCreatinine and eGFR results as well as AST and ALT values measured in the local laborator yfor screening . Current laboratory results available 
for th e index hospi[INVESTIGATOR_885720]. Full safety labs done at randomization (C entral Lab).
fThe visit can be performed at a later time point if participant on inpatient rehabilitation facility and this visit can notbe arranged.
g  Refer to Table 1–1:PK, PD and Biomarker sampling
h  Outcome events including all bleeding, death, MI, stroke and stent thrombosis as well as events indicative of a potential outcome (see Section 
[IP_ADDRESS] )need to be reported on  dedicated form sin the eCRF on an ongoing basis, even if the participant is permanently discontinued from 
the study treatment.
iat visits 3 , 5, 7, 9 and 11: any new concomitant medication and AEs or outcome events will be captured during the telephone calls.
j“Study drug ”refers to “study intervention’ as defined in Section 6.1.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  13of 78
PK, PD and Biomarkers sampling
An overview of the PK, PD and Biomarkers sampling is shown in Table 1–1
Table 1–1PK, PD and Biomarker Sampling
Day 1
(Visit 2)Week 4 
(Visit 4a)Week 4 or later
(Visit 4
or subsequent 
visit)Week 26 
(Visit 8) /ETd
Predose 
Day 1Predose 0.5-1.5h 
postdose2-4hb
postdose4-12hb,c
postdosePredose
PKex x x x x
PDex x x x x x
Biomarker
s Plasma x x
Biomarker
s Serum x x
Genetics x
Abbreviations: ET =Early termination, PD = pharmacodynamic(s), PK = Pharmacokinetic(s)
aAt Visit 4: in order to collect pre- dose samples for PK and PD , participants should take their study 
drug at the site only after blood sampling . The investigator must record the time when the study drug
is taken at the site . A phone call before V4 to remind participants is recommended.
b  The minimum time bet ween the [ADDRESS_1239133] -dose sample can be taken at week 4 (visit 4) or at a later-on visit (e .g.
Visit 6). The exact time of when the study drug was administered must be recorded as well as PK 
and PD post -dose sample collection time.
dAt Visit 8 (week 26) participants should take their study  drug at the site, in order to collec t pre-dose 
samples for PK/PD and biomarkers. However, i n case Visit 8 is also the EOT visit as well as i n case 
of ET visit, no study  drug will be administered.
eIf study drug is temporily stopped, PK/PD blood samples should only be obtained if study drug has
been restarted and sustained for  at least [ADDRESS_1239134] recent / associated study  drug intak e(i.e. on the PK/PD sampling day, as well as the previous 
day).
2. Introduction
BAY [ADDRESS_1239135], potent inhibitor of activated coagulation factor XI (FXIa) being 
developed for three main indications:
1. Prevention of stroke and systemic embolism in patients with AF (cardioembolic stroke 
prevention) 
2. Secondary  stroke prevention in patients after an ischemic stroke (large artery , lacunar 
stroke, or embolic stroke of undetermined source [ESUS]) (non- cardi oembolic stroke 
prevention)
3. Prevention of major adverse cardiac events (CV death, MI, stroke) in patients after an
acute myocardial infarction (AMI).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  14of [ADDRESS_1239136] placebo in patients following an AMI who are treated with dual 
antiplatelet therap y. 
The current clinical development of BAY 2433334 includes two additional Phase 2 studies in 
patients with AF (stud y [ZIP_CODE] , 3 months treatment duration, api[INVESTIGATOR_885721] ) and in 
patients with non -cardioembolic ischemic stroke (study  [ZIP_CODE], 6- 12 months treatment 
duration, on top of primarily  single antiplatelet therap y, placebo as comparator ). 
Each individual study  will have its own objectives. However, in order to reach and draw 
conclusions concerning safet y in general, and especially  bleeding, the program is designed to 
pool the data across the three Phase 2 studies to help further characterize safet y and efficacy.
2.1 Study Rationale
This Phase 2 study  will explore a dose range of BAY 2433334 in order to determine the dose 
that is efficacious and safe and that can be used in a Phase 3trial in the same indication.
The benefit of the concept of adding anticoagulation to antiplate let treatments has been 
proven b y rivaroxaban forACS in the ATL AS TIMI  51 trial (rivaroxaban in addition to single 
or dual antiplatelet therapy  consisting of a cetylsalicy lic acid [ASA] +/-clopi[INVESTIGATOR_7745]) , and for
patients with stable CAD/PAD in the COMPASS trial ( rivaroxaban in addition to ASA ).
However ,its clinical use in ACS is limited, as patients and healthcare providers are concerned 
about the bleeding risk for triple therap y including 2 antiplatelet therapi [INVESTIGATOR_014] (ASA + P2Y 12
inhibitors) and an anticoagulant. 
The use of BAY 2433334, as an oral FXIa inhibitor ,could address this concern, as it is 
expected not tolead to a relevant increase in bleeding and especiall y major bleeding, while 
maintaining the efficacy benefit of a combination of antiplatelet therapi[INVESTIGATOR_885722]. This is based on the available preclinical data , data from patients with inherited 
FXI deficiency  and first clinical data from two Phase 2 proof -of-concept studies in patients 
undergoing total knee replacement (please see Section 2.3).
BAY [ADDRESS_1239137] common cause of mortality worldwide, and the majority  of CV 
mortality  is attributable to coronary  heart disease (CHD). The incidence and prevalence rates 
of CHD remain high throughout the developed world. I n the [LOCATION_002] (US), the 
American Heart Association (AHA) reported that the prevalence of CHD in adults ≥20 y ears 
of age is 7.0%. Acute my ocardial infarctio n isa subcategory  of C HDand t ypi[INVESTIGATOR_885723]. The majority  of m yocardial infarction sarise from an 
acute rupture of an atherosclerotic plaque that leads to a complete blockage of the blood flow 
in acoronary  arter y and consequentl y damage of the heart .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  15of 78
According to a current report of the American Heart Association, the prevalence of M I is 
3.1% of US adults (7.9 Million US Americans), and the annual incidence rate of MI in the US 
is 935,000. Within one year after MI, 19% of men and 26% of women aged 45 y ears and 
older will die. 
2.2.2 Treatment Guidelines
Following an acute my ocardial infarction, patients remain in a persistent hypercoagulable  
state and are at risk for adverse thromboembolic events. European Societ y of Cardiology  
(ESC)/European Association for Cardio- Thoracic Surgery  (EACTS) guidelines ( Valgimigli et 
al. 2018) recommend that in patients with ACS , regardless of initial treatment strategy,  
DAPT with a P2Y 12inhibitor combined with ASA is recommended  for 1 2 months unless 
there are con traindications such as excessive risk for bleeding .
Similar guidelines are available from the ACC/AHA. The AHA guidelines (AHA/ACC 2014)
also recommend [ADDRESS_1239138] that the duration of DAPT be adjusted to the individual patient’s risk of 
recurrent ACS vs. risk of bleeding.
2.2.3 FXIa Inhibitor: Mode of A ction
BAY [ADDRESS_1239139], potent inhibitor of activated coagulation factor XI (FXIa). 
The plasma serine protease zy mogen factor XI (FXI) is activated after initiation of the contact 
[CONTACT_885737] (FXIIa) and during the amplification phase as part of a 
positive feedback loop through activation b y thrombin. FXIa is though t to contribute strongl y 
to clot progression, which may  potentiall y lead to vessel occlusion and pathological 
manifestations of thrombosis, but has minor impact on hemostasis due to its limited role in the 
initiation phase of the extrinsic pathway . 
FXIa i nhibition by  [CONTACT_55865] 2433334 may  offer the opportunity  to prevent thrombosis without 
interference with primary hemostasis and to thereby  [CONTACT_55866] a paradigm shift compared to Vitamin 
K antagonists and Non -Vitamin K oral anticoagulants (NOACs).
Figure 2–[ADDRESS_1239140] activation

CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  16of 78
Source: adapted from ( Chen et al. 2014 )
2.2.4 BAY 2433334
[IP_ADDRESS] Preclinical / Toxicology Data
Preclinical data using FXI -deficient mice or studies using pharmacological inhibition of FXIa 
in different animal models, for example a FeCl-induced thrombosis model, show ed a benefit 
in reduced thrombus formation. The data indicate that higher efficacy  might be possible to 
achieve when compared to the therapeutic doses of NOACs. 
The benefit in these animal models was combined without an associated increase in bleeding 
time as is seen for NOACs in these models. I mportantly , no further increase in bleeding time 
was seen even when BAY 2433334 was given on top of dual antiplatelet therap y.
Data regarding toxicology  studies as well as more preclinical data can be found in the 
Investigator`s Brochure but are also partly  described in the benefit/risk section (see Section 
2.3).
[IP_ADDRESS] Clinical Data
So far, [ADDRESS_1239141] received trea tment with BAY 2433334 in doses 
ranging from 5 mg to 150 mg after single dosing and up to 100 mg once daily  inmultiple 
dose settings. 
Safety
Thesingle dose escalation study  (study  [ZIP_CODE]) with BAY [ADDRESS_1239142] study  part 
with 25 mg .No clinically relevant signs or s ymptoms of bleeding were observed.
The multiple dose escalation study (study [ZIP_CODE]) has also been clinically  completed and 
evaluation is still ongoing. Therefore, the results are preliminary . It consisted of three parts: 
Part A, wherein 25 mg, 50 mg and 100 mg BAY 2433334 were given once daily  over 9 
consecutive days, part B, where 25 mg were given twice dail y, and part C , where a 
midazolam interaction was investigated with 25 mg and 75 mg BAY 2433334.
Overall, BAY 2433334 was safe and well tolerated. More details on safety  can be found in the 
Investigator`s Brochure.   
Pharmacodynamics 
The following pharmacody namic parameters were investigated in both the FiM study  (study  
[ZIP_CODE]) and MDE stud y (study  [ZIP_CODE]): aPTT, FXI activity (AXIA assay ), and FXI 
concentration. Bleeding time was investigated after single dose administration only  (study  
[ZIP_CODE])
A dose dependent prolongation of aPTT was observed after single dosing with a close direct 
correlation between aPTT and plasma concentration:
In the 25 mg OD dose step of the multiple dose ( MD)study  [ZIP_CODE] a prolongation of 
aPTT of  (mean, compared to baseline) after single do sing and  (mean) at 
steady  state was seen. 
CCI
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  17of 78
In the 50 mg OD dose step of the MD study [ZIP_CODE] a prolongation of aPTT of  
(mean, compared to baseline) after single dosing and  (mean) at steady  state 
was seen. 
In the 100 mg OD dose step of the MD stud y [ZIP_CODE] a prolongation of aPTT of  
(mean, compared to baseline) after single dosing and  (mean) at steady  state 
was seen. 
FXI activity  (AXIA assay ) is inhibited by  a mean of ~ 85% after 25 mg SD and a mean of 
~95% (25  mg OD) at steady  state. After 50 mg and 100 mg SD and MD, activated FXI 
activity  is inhibited by  a mean of >95% both after first dose and at stead y state. The duration 
of the inhibition of FXI activity  (AXIA assay ) is dose dependent. Complete inhibition was 
reported for 12 hours for 50 mgat stead y state and this is prolonged up to 24 hours for 100 
mg at stead y state. 
Pharmacod ynamic parameters aPTT and FXI activity  correlated well with observed plasma 
concentrations of BAY 2433334 .
No relevant changes of FXI concentration or PT were observed in either study . 
No clinically  relevant changes in bleeding time were observed after single dose application. 
Pharmaco kinetics
The key pharmacokinetics features of BAY 2433334 based on current available data and 
when administered as IR tablets can be summarized as follows. 
BAY 2433334 is absorbed with a median time to reach maximum plasma concentration 
(tmax) of 2 to 4 hours (fasted state) .
There is no hint for an y deviation f rom dose- proportionality  found for doses between 
5mg and 150 mg.
Relative bioavailability  of BAY 2433334 administered as IR tablet amounted to 
approximately  89.5% with regard to AUC and of 86.0% with regard to C maxcompared to 
administration as an oral s olution.
A high -fat, high -calorie meal has minor effect on the AUC of 25 mg BAY 2433334 
(decrease of 12.4%) and results in a reduced absorption rate (31.4% decrease in maximum 
plasma concentration [C max] and 2.5 h prolongation in t max).
The variabilit y was low to moderate for AUC and C max(%geoCV approx. 15 to 30%).
The degree of accumulation of BAY 2433334 is low regarding C max,md or AUC τ,mdafter 
once dail y multiple dosing with R ACmaxbetween 1.4 and 1.6 and R AAUC between 1.5 and 
1.7.
Pharmacokinetics were linear over time.
The metabolite M -10 (BAY 2826102, formed b y amide hy droly sis of the central amide 
and subsequent N -acetylation) is expected to be a main compound in human plasma with a 
metabolic ratio to parent drug of approx. 24 to 30%. This metabo lite is not 
pharmacologically  active.
CCI
CCI
CCI
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  18of 78
Terminal half -life is 14.0 to 17.4 hours supporting once dail y dosing.
Low apparent oral plasma clearance (CL/F) of about 3.19–4.27 L/h was observed in 
geometric mean (corresponding to a blood clearance/F of 4.54 -6.07 L/h).
Based on preliminary  evaluation of the 50 mg dose step in the multiple dose escalation 
study  (study  [ZIP_CODE]) renal elimination was low ( 15%).  
Based on the preliminary ethnic evaluation up to the 50 mg dose step of single and 
multiple dose in Caucasians (study [ZIP_CODE]) and Japanese (study [ZIP_CODE]), there is no large 
difference in PK between races though geometric mean of AUC and C maxin Japanese 
were slightly  higher than in Caucasians. 
Based on preliminary  evaluation the strong CYP3A4 inhibitor itraconazole increased 
BAY 2433334 exposure by  100% (2-fold) while maximum plasma concentrations were 
not changed (stud y [ZIP_CODE]). Terminal half -life was prolonged from 16 to 29 hours .
More details can be found in the I nvestigator’s Brochure.  
2.3 Benefit/Risk Assessment
The FXIa inhibitor BAY [ADDRESS_1239143] a lower risk for clinically significant 
bleeding when compared to other oral anticoagulants (VKAs and NOACs) is not expected to 
increase the risk for clinically  significant bleeding, while leading to an efficacy  benefit.
The expected clinical profile of BAY [ADDRESS_1239144]  unaff ected, that is
activated in case of vessel injury . 
At this stage of development there is no clinical evidence available yet to confirm the efficacy  
benefit of BAY 2433334. However, the data supporting that this compound is expected to 
lead to prevention o f thrombosis events in the intended indication s are the following: 
FXI-deficient knockout mice are protected from thrombosis. In addition, in various 
thrombosis models in rabbits, BAY 2433334 demonstrated reduced thrombus weight, and this was seen when given with or without antiplatelets. While therapeutic doses of NOACs lead to a 20 -30% reduction in thrombus formation in the same animal models, 
BAY 2433334 was able to reduce the thrombus formation by  [CONTACT_8622] ~ 90%.
In people with inherited Factor XI deficiency, a rare coagulation deficiency  caused b y 
either reduced production of factor XI or b y production of a loss -of-function factor XI 
molecule , a lower risk for venous thromboembolic events as well as cardiovascular 
events and especiall y stroke has been reported. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  19of 78
Increased levels of FXI are reported as a risk factor for ve nous thromboembolism and 
myocardial ischemia or stroke. Whether there is a causal relationship is unclear.
A first proof of concept targeting FXI as anticoagulant has been shown b y a FX I 
Antisense Oligonucleotide. Reducing FXI levels in patients undergoing total knee 
arthroplast y (TKA) led to an improved prevention of postoperative venous 
thromboembolism (VTE), when compared to enoxaparin. Based on modeling 
approaches, the inhibition levels of FXIa activity  in the stud ycan be achieved with the 
20 mg and 5 0 mg doses of BAY 2433334 (see also the I nvestigator’s Brochure).
Phase [ADDRESS_1239145] planned dose of 50 mg to be tested in Phase 2 lead to
complete of inhibitio n during 12 hours of the day . This was combined with a mean 
prolongation of aPTT of . 
At this stage of development, the safet y profile has not been established. The following 
information related to safety  as well as potential risks for patients is available:
1. Bleeding is the main safety  concern related to antithrombotic therapi[INVESTIGATOR_014]. For an inhibitor 
of FXIa a lower bleeding risk is expected. Data supporting this are listed below :
oFXI-deficient knockout mice do not show as bleeding phenot ype. In additi on, 
in the thrombosis animal models no increase in bleeding time (gum and ear) 
was reported. Importantly , no further increase in bleeding time was seen when 
BAY 2433334 was given on top of dual antiplatelet. I n addition, in the 
toxicology  studies no releva nt bleeding was reported for up to 37- fold the 
expected human exposure of the planned 50 mg multiple dose in patients.
oPatients with inherited FXI deficiency  are t ypi[INVESTIGATOR_885724] a prolonged activated partial thromboplastin time (aPTT) in routine 
clinical testing. There is no direct association between FXI activity  levels and 
bleeding risk, though historically  and predominantly  in the Ashkenazi Jewish 
population, FXI deficiency  has been categorized as having a mild bleeding 
phenoty pe that generall yonly manifests following injury  or trauma in tissues 
with high fibrinol ytic activity .
oIn the completed and ongoing Phase 1 studies conducted with BAY 2433334, 
no relevant bleeding events were reported so far.
A risk for bleeding cannot be excluded in patients after an acute my ocardial infarction 
included in the Phase 2 study  especiall y as patients will be treated on top of dual 
antiplatelet therap y. Therefore, bleeding will be closely  monitored in the study  and will 
be adjudicated b y an independent clinical event committee.
2. In toxicology  studies, the liver was identified as a  target organ in the rat but not in the 
dog. This included dose-dependent spontaneous, mostly  transient increases in liver 
enzy mes in single animals without clear corr elation to histopathological findings in the 
livers . Based on this, patients with a >2.[ADDRESS_1239146] in the 
study . 
CCI
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  20of [ADDRESS_1239147] been safe and well tolerated. This included general safety , 
laboratory , vital signs and ECGs. The doses were 2 and 3 -fold higher than planned in 
this Phase 2 study .
4.Based on prelimin ary evaluation the strong CYP3A4 inhibitor itraconazole increased 
BAY 2433334 exposure by  100% (2-fold) while maximum plasma concentrations were 
not changed (stud y [ZIP_CODE]). Terminal half -life was prolonged from [ADDRESS_1239148] an independent data 
monitoring committee (IDMC) will monitor the safet y of all participants enrolled in all 3 
Phase 2 studies with a focus on bleeding and general safet y.In addition, a focus of the IDMC 
review will be on an y stroke occurring during the study .
Several F actor XI (FXI) and activated Factor XI (FXIa) inhibitor assets are currentl y in 
development as antithrombotics, including antisen se oligonucleotides (ASOs), antibodies and 
small molecules (SMOL s).
In summary , in this Phase [ADDRESS_1239149] time BAY 2433334. Study  drug will be given  on top of their usual therapy  with dual 
antiplatelet therap y. The main objective of the study  is to evaluate whether the addition of 
BAY 2433334 will lead to no relevant increase in bleeding when given on top of dual 
antiplatelet therap y and that this is combined with a treatment benefit in terms of reduction of 
CV death, MI , stroke and stent thrombosis.  An additional objective is to guide dose selection 
for Phase 3. Currently , available preclinical and clinical data from the ongoing study  
regarding the key  risks do not indicate an unfavorable risk profile for BAY 2433334. The 
overall risk is anticipated to be acceptable in the context of the drug benefit .
More detailed information about the known and ex pected benefits and risks and reasonabl y 
expected adverse events of BAY 2433334 may  be found in the Investigator’s Brochure.
3. Objectives and Endpoints
Objectives and endpoints (primary  and exploratory ) of the study  are reported below, in Table 
3–1. Please refer to Section 9.4 for further details.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  21of 78
Table 3–1 Ob jectives and Endpoints
Objectives Endpoints
Primary
to evaluate whether the oral FXIa 
inhibitor BAY 2433334 compared to placebo leads to a lower incidence of 
CV death, MI, stroke and stent 
thrombosis in participants withan acute 
myocardial infarction and who are
treated withdual antiplatelet therapyPrimary Efficacy Endpoint
the composite of CV death, MI, stroke and stent thrombosis 
Secondary Efficacy Endpoints
all cause mortality
CV death
MI
stroke
stent thrombosis
to evaluate whether the incidence of 
bleeding is similar for BAY 2433334 compared to placebo in participants 
withan acute m yocardial infarction and 
who are treated withdual antiplatelet 
therapyPrimary Safety Endpoint:
Bleeding Academic Research 
Consortium (BARC) classification
definition type 2, 3 and 5   
Secondary Safety Endpoints
all bleeding
BARC bleeding definition type 3, 5
BARC bleeding definition type 1,2,3,5
Exploratory Safety Endpoints
TIMI clinically significant bleeding events 
TIMI major bleeding events
TIMI minor bleeding events
ISTH major and clinical relevant non -
major bleeding
ISTH major bleeding
Exploratory
to explore additional pharmacokinetic 
and pharmacodynamic parameters, 
biom arkers and genetics
to further investigate the study  
intervention and similar drugs (i.e. mode-of-action -related effects and / or 
safety ) and to further investigate 
pathomechanisms deemed relevant to 
cardiovascular diseases and 
associated health problemsOther Exploratory Endpoints
FXIa inhibition, aP TT
Pharmacokinetics
Various biomarkers and genetics may be explored  (e.g. diagnostic, safety, 
pharmcodynamic , monitoring, or 
potentially predictive biomarkers)  
Abbreviations: aPTT =activated partial thromboplastin time, BARC =Bleeding Academic Research 
Consortium, CV = cardiovascular, ISTH =International Society on Thrombosis and Hemostasis, 
MI=myocardial infarction, PD= pharmacodynamic, TIMI =Thrombolysis i n myocardial infarction
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  22of [ADDRESS_1239150] ratio of the composite of CV death, MI, stroke 
(ischemic and hemorrhagic) and stent thrombosis comparing BAY 2433334 (20 and 50 mg
pooled) with placebo in adult participants with an AMI treated with DAPT while alive and 
regardless of treatment discontinuation.
The secondary  efficacy  estimand saredefined following the same approach for the individual 
secondary  endpoints as done for the primary  efficacy  estimand.
The primary  safet y estima nd is the hazard ratio of BARC ty pe 2, [ADDRESS_1239151] one dose of stud y intervention of BAY 2433334 or placebo and while 
the patient is alive and exposed to study  drug .
The secondary  safet y estimands aredefined following the same approach for the individual 
secondary  endpoints as done for the primary  safety  estimand.
4. Study Design
4.1 Overall Design
Study [ZIP_CODE] is a multicenter , randomized , placebo controlled, double -blind, parallel group, 
dose-finding phase 2 study . Figure 1–1display s the overall study  design.
Approximately  1600 participants ( 400 per arm) from approximately  150 study  centers 
worldwide will be randomized 1:1:1:1 to one of the three investigational drug arms (BAY 
2433334) or to the placebo arm , in addition to their SoC dual antiplatelet background therap y
(for details see Section 6.5).
Stratification will be based on the intended P2Y 12 inhibitor use (ticagrelor/prasugrel versus 
clopi[INVESTIGATOR_7745]) after hospi[INVESTIGATOR_2345]. The number of participants with STEMI  enrolled in the study  will be limited to no more than 
50% of all participants.The maximum duration of study  participation is planned to be approximately  55 weeks, 
consisting of:
Screening Period   (Visit 1 until Visit 2) : ≤ 5days 
Participants will be screened and have to be randomized during hospi[INVESTIGATOR_885725] 5days of hospi[INVESTIGATOR_063]. Participants should
have the initial coronary  angiography  and revascularization procedures, either 
percu taneous coronary  intervention (PCI) or coronary  artery  by[CONTACT_15806] (CABG), 
as treatment for the index AMI  event performed before randomization. However, a 
planned, staged PCI procedure can be performed after randomization.  If all information is available, participants can be randomized on the day  of screening.
Treatment Period ( from Visit 2 through Visit 12) : Minimum 26 weeks and 52 
weeks maximum The duration of the planned double -blind interventional treatment for each participant 
will be 26 to 52 weeks.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  23of [ADDRESS_1239152] a total 
treatment duration of a minimum 26 weeks to a maximum of 52 weeks.
Safety Follow -up Period ( Visit 13) : 14 day s (+ 7 day s) after EoT or ET
Study  visits wi ll take place as visits at the study  sites   and telephone calls. Visitsat the study  
sites take place at screening and randomization (V isit 1 and V isit 2), at Week 4 (Visit 4) , 
Week 13 (V isit 6), Week 26 (V isit 8), Week 39 (V isit 10) and at W eek 52 / EoT ( Visit 12). 
Telephone calls take place at Week 2 (Visit 3) , Week 8 (Visit 5) , Week 20 (Visit 7) , Week 32 
(Visit 9) and at Week 46(Visit 11), as well as 2 weeks after the end of treatment visit ( i.e.
safet y follow-up, Visit 1 3).
For participants who prematurely  discontinue from the study  drug, an ET visit (Visit 12a) 
should take place as soon as possible as on -site visit. Participants are asked to continue the 
study  schedule of visit suntil completing all the study visits or end of stud y is declared. 
Telephone calls take place 14 day safter ET visit (i.e. Safet y follow- up, Visit 13).Further 
details are reported in Section 7.1.
Details of study  procedures and their timing are summarized in the SoA (Section 1.3).
4.[ADDRESS_1239153] different degrees of FXIa inhibition and 
determine the dose to be tested in Phase 3.
Study [ZIP_CODE] is a multicenter, randomized, placebo controlled, double -blind, parallel group, 
dose-finding Phase 2 study  in patients after an AMI . The study will apply  the principles of 
randomization, stratification ( by [CONTACT_587583] P2Y 12inhibitor use [ticagrelor/prasugrel ver sus 
clopi[INVESTIGATOR_7745] ]after hospi[INVESTIGATOR_2345] ) and double -blinding in order to prevent  bias in the 
inclusion of patients or reporting of safet y or efficacy events. 
In addition, the study will follow a parallel group design in order to prevent bias in the data 
due to e.g. different sites in different countries enrolling at different timepoints into the study  
or in case of any seasonally  related differences. There does not appear to be a requirement for 
a dose escalation approach, because based on the available preclinical and clinical data for 
BAY2433334 there are no safet yconcerns related to the highest dose of [ADDRESS_1239154] therap y with dual antiplatelet therap y leads to a lower incidence of 
major CV events (CV death, stroke, MI and stent thrombosis) and without increa sing the 
incidence of bleeding.
CV death, MI, stroke and stent thrombosis are used to assess efficacy  in this study  and have 
been used as endpoints in earlier studies in patients with an acute coronary  syndrome or acute 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  24of 78
myocardial infarction . Bleeding will be primaril y assessed using the BARC bleedin g 
definition. 
Participants will be treated on top of dual or later single antiplatelet therap y as prescribed b y 
their treating ph ysician. The choice of P2Y 12inhibitor therap y (ticagrelor, clopi[INVESTIGATOR_885726] ) and duration of treatment with DAPT afte r hospi[INVESTIGATOR_885727] , 
will be left to the discretion of the treating ph ysician and should follow local standard of care 
guidelines. Thus, the study  background therapy  will reflect how patients are normally  treated 
and also allows to asse ss the combination of the study  drug with different P2Y 12inhibitors 
(clopi[INVESTIGATOR_7745], ticagrelor, prasugrel) rather than requiring the same for all participants.
4.[ADDRESS_1239155] the once dail y dose of 10 mg (low dose), 20 mg (mid dose) and 50 mg 
(high dose) dose of BAY 2433334. The selection of the high dose in  this study  was not limited by  [CONTACT_49750] y and tolerability data 
from toxicology  studies, nor from the results of the human Phase 1 studies conducted in 
healthy  volunteers.  Single doses up to 150 mg or multiple doses u p to 100 mg once dail y for 
9 day s were tested in the Phase I studies. Due to these favorable results , the dose selection for 
the Phase 2 studies was primarily based on pharmacody namic assay s (precli nical and Phase 1 
studies) including aPTT and FXIa activity . 
Modeling approaches of the available Phase [ADDRESS_1239156] range of inhibition of FXIa and lead to 
different degrees of increases in aPTT (Table 4–1).
The high dose of 50 mg was chosen to reach significant inhibition of FXIa and to 
achieve maximum efficacy . However this dose should not lead to a complete 
inhibition of FXIa during the majority  of the day . The selected 50 mg dose is expected 
to lead to a mean FXIa activity of 7 % with FXIa activity  <10% during 14 hours of the 
day. aPTT is predicted to increase to  at trough and  at peak. 
The mid dose of [ADDRESS_1239157] a linear dose 
response related to FXIa inhibition. This dose leads to a mean FXIa activity of 23%
10 mg was selected as the low dose, as lower doses lead to no or only minimal 
increases in aPTT. For the 10 mg dose, the expected mean FXIa activity  is 45% and 
aPTT is increased to  at trough and  at peak. 
Table 4–1BAY 2433334: dose selection 
Humans, multiple dose, 
modelled
OD dosingPredicted FXIa activity Predicted aPTT increase
Trough % Peak % Mean % Trough % Peak %
50 mg 13 3 7
20 mg 40 11 23
10 mg 67 27 45
Abbreviations: aPTT = activated partial thromboplastin time , OD =once a day
CCI
CCI
CCI
CCI
CC
I
CC
I
CC
I
CC
I
CC
I
CC
I
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  25of [ADDRESS_1239158] completed the study  if he/she has completed all phases of 
the study  including the last scheduled study visit.
The end of the stud y is defined as the date of the last visit of the last participant in the study 
globall y.
5. Study Population
The study will enroll adult participant s during hospi[INVESTIGATOR_885728] 5 day s of hospi[INVESTIGATOR_885729] .The number of participant s with STEMI  enrolled in the study  
will be limited to no more than 50% of all participant s.
Prospective approval of protocol deviation s to recruitment and enrollment criteria, also known 
as protocol waivers or exemptions, is not permitted.
5.[ADDRESS_1239159] y:
Age
1.Participants must be 45years of age or older , at the time of signing the informed consent
Type of Participant and Disease Characteristics
2.Acute myocardial infarction1(excluding MI associated with PCI  or CABG 
revascularization procedures) with :
a.clinical sy mptoms of a cute m yocardial infarction  AND
b.elevated biomarkers of myocardial necrosis (creatine kinase -muscle and brain 
isoenzy me [CK -MB] or cardiac troponins) AND
c.at least one of the following risk factors need to be fulfilled:
i.Age ≥ 65 y ears
ii.Prior MI (before the index AMI  event)
iii.Prior peripheral arterial disease
iv.Diabetes Mellitus
v.Prior coronary  artery  by[CONTACT_15806] (CABG)
AND
                                                
1Differentiation  will be made betw een ST elevation myocardial infarction (STEMI) and non -ST elevation 
myocardial infarction (NSTEMI). For diagnosis of STEMI the following criteria will need to be fulfilled:
Elevation of ST -segm ent more than 0.1 millivolt (mV) in [ADDRESS_1239160] ion
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  26of 78
d. initial angiograph y and revascularization procedures, either PCI or CABG ,as 
treatment for the index event performed before randomization . (Note:a planned ,
staged PCI procedure can be performed after randomization )
3.Plan for dual antiplatelet therap y (ASA + P2Y 12inhibitor )after hospi[INVESTIGATOR_885730]
4.Randomization during hospi[INVESTIGATOR_885731] A MI event and latest within 5days of 
hospi[INVESTIGATOR_885732]
5. Capable of giving signed informed consent as described in Section 10.1.3 which includes 
compliance with the requirements and restrictions listed in the informed consent form 
(ICF) and in this protocol . Written informed consent has to be signed before an y stud y-
specific procedure. 
5.2 Exclusion Criteria 
Participants are excluded from the study  if any  of the following criteria apply :
Medical Conditions
1.Hemody namicall y significant ventricular arrhy thmia s or cardiogenic shock at time of 
randomization
2.Uncontrolled h ypert ension ( systolic blood pressure ≥ 160 mmHg or diastolic blood 
pressure ≥ 100 mmHg )at randomization
3. Active bleeding; known bleeding disorder, history  of major bleeding (intracranial, 
retroperitoneal, intraocular) or clinical lysignificant gastrointestinal bleeding within last 
[ADDRESS_1239161] 30 day s of index event  
5. Known significant liver disease (e.g. acute hepatitis, chronic active hepatitis, cirrhosis) 
or hepatic insufficiency  classified as Child- Pugh B or C (see Section 10.6), or ALT or 
 AST >  2.5 x the upper limit of normal, measured as part of the hospi[INVESTIGATOR_885733]
6.Estimated glomerular filtration rate (eGFR) < 30 mL /min/1.73 m2  calculated by 
[CONTACT_126271] (MDRD) formula (see Section 10.7), determined as part of the hospi[INVESTIGATOR_885734]  
7.Major surgery  during last 30 day s or planned major surgery or intervention within 
study  period
8.Known allergy , intolerance or hy persensitivity  to either of the study interventions 
(active substance or excipi[INVESTIGATOR_840])
Prior/Concomitant Therapy
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  27of 78
9. Planned use or requirement of full dose and long term anticoagula tion therapy  during 
study  conduct2
10.Anticipated need for chronic (more than 4 weeks) therap y with NSAIDs 
11.Concomitant use of an y of the following therapi[INVESTIGATOR_6523] 14 days (or at least five half -
lives of the active substance whatever is longer) before randomization and first study  
intervention administration (see Section 6.5):
Strong inhibitors of cy tochrome P450 isoenzy me 3A4 (CYP3A4) e.g. human 
immunodeficiency  virus protease inhibitors, sy stemically  used azole -antimy cotic 
agents, clarithrom ycin or telithromy cin
Strong inducers of CYP3A4, e.g. phen ytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, 
rifampi[INVESTIGATOR_55839]. John’s wort
Other
12. Known current alcohol and/or illicit drug abuse that may  interfere with the participant s 
safet y and/or compliance at the discretion of the investigator
13. Women of childbearing potential (women are considered of childbearing potential if 
they are not surgically  sterile or postmenopausal, defined as amenorrhea for > 12 
months) .Male participants not willing to use condoms when sexually  active with a 
woman of childbearing potential
14.Close affiliation with the investigational site or sponsor; e.g. a close relative of the 
investigator, or a dependent person (e.g. employ ee or student of the investigational site 
or the sponsor)
15.Previous (within 30 day s or 5 half -lives of the investigational drug, whichever is 
longer) or concomitant participation in another clinical study  with investigational 
medicinal product(s) or device(s). Registries and observational studies are allowed.
16.Any condition or therapy, which would make the participant unsuitable for the study  
(e.g. non- compliance , dysphagia with inability to swallow study  intervention ) or 
otherwise vulnerable (e.g. participant in custody by [CONTACT_681203] y or a court), or 
a life -expectancy  < 6months 
5.[ADDRESS_1239162] yle (except for the above 
mentioned substance abuse) and / or diet appl y.
5.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study  but 
are not subsequently  randomly  assigned to study  intervention. A minimal set of screen failure 
information is required to ensure transparent reporting of screen failur e participants to meet 
                                                
2Not  applicable to DVT prophylaxis with LMWH or unfractionated heparin for short periods of time.  
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  28of 78
the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements and to 
respond to queries from regulatory authorities. Minimal information includes demography , 
screen failure details, and eligibility  criteria.
Indivi duals who do not meet the criteria for participation in this study  (screen failure) must 
not be rescreened.
6. Study Intervention
Study  intervention is defined as any  investigational intervention (s), marketed product(s), 
placebo or medical device(s) intended to be administered to a study  participant according to 
the study  protocol.
6.1 Study Intervention(s) Administered
The following stud y interventions will be administered in the stud y:
BAY 2433334 :sponsor ’s study  drug under investigation
Placebo to BAY 2433334
BAY 2433334 is supplied in various strengths as film -coated, immediate -release tablets  with 
identical appearance. Theimmediate release tablets will be provided as pi[INVESTIGATOR_8745], oval, film-
coated tablets containing either 5 mg, 15 mg or 25 mg of BAY 2433334 ( Table 6–1).
The study  intervenions (tablets) are not to be broken, halved or crushed, and should be 
swallowed whole with a glass of water in the morning .Partic ipants will have to take two 
tablets from two different bottles (one tablet from each bottle) for one dose. Study  drug 
(tablets) can be taken irrespective of food intake.
Matching placebos for BAY [ADDRESS_1239163]. 
Missed study interve ntion dose
The planned double -blind treatment phase starts at randomization and ends at week 52 or the 
study  treatment end date (i.e. [ADDRESS_1239164] participant of the study has been 
randomized), whichever is earlier, or when stud y drug is permane ntly discontinued. Study  
drug will start as soon as possible after randomization (day  1), and is expected to continue 
through the end of the planned treatment period as described above.
If a dose of study  intervention is missed , the participant should take a dose immediately  on 
the same day . The dose should not be doubled to make up for a missed dose. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  29of 78
Table 6–1Study interventions
Arm name [CONTACT_55865] 2433334 
high dose BAY 2433334 
medi umdoseBAY 2433334 
lowdosePlaceb o
Intervention 
NameBAY 2 433334 BAY 2 433334 BAY 2 433334 Placebo
Type Drug Drug Drug Placebo
Dose 
formulationtablet tablet tablet Tablet
Unit dose 
strengths25 mg 5 mg and 15 mg 5 mg N/A
Dosage 
Level(s)50 mg 20 mg 10 mg N/A
Frequency Once a day in 
the morningOnce a day in 
the morningOnce a day in 
the morningOnce a day in 
the morning
Route of 
Administrationoral Oral oral Oral
Use experim ental experim ental experim ental Placebo
IMP/AxMP IMP IMP IMP IMP
Packaging and 
LabelingHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsuleHDPE bottles 
with desiccant 
capsule
Abbreviation: AxMP = auxiliary medicinal product; IMP= investigational medical product; NA= not 
applicable
All study  interventions will be labelled according to the requirements of local regulations .
For administered stud y interventions, a system of numbering in accordance with all 
requirements of Good Manufacturing Practice (GMP) will be used, ensuring that each d ose 
can be traced back to the respective bulk batch of the ingredients.
A complete record of batch numbers and expi[INVESTIGATOR_55840]’s study  file.
In all case s BAY [ADDRESS_1239165] of care, consisting of 
antiplatelet therap y. The choice of antiplatelet therapy will be left to the discretion of the 
treating ph ysician and can include single or dual antiplatelet therapy  (see Se ction 6.5.1).
The choice of background antiplatelet therapy will be documented in the patient records and 
captured in the eCRF.
6.2 Preparation/Handling/Storage/Accountability
All study  interventions will be stored at the investigational site in accordance with Good 
Clinical Practice (GCP) and Good Manufacturing Practice (GMP) requirements and the instructions given b y the clinical supplies department of the sponsor or its affiliates.
1.The investigator or d esignee must confirm appropriate temperature conditions have 
been maintained during transit for all study  intervention received and any  
discrepancies are reported and resolved before use of the study  intervention.
2.Only  participants enrolled in the study may receive study  intervention and only  
authorized site staff may  supply  or administer study  intervention. All study  
intervention must be stored in a secure, environmentally  controlled, and monitored 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  30of 78
(manual or automated) area in accordance with the label ed storage conditions with 
access limited to the investigator and authorized site staff.
3.The investigator, institution, or the head of the medical institution (where applicable) 
is responsible for stud y intervention accountability, reconciliation, and r ecord 
maintenance (ie, receipt, reconciliation, and final disposition records).
4.Further guidance and information for the final disposition of unused study  
interventions are provided in the Investigator Site File . 
6.3 Measures to Minimize Bias: Randomizatio n and Blinding
All participants will be centrally  assigned to randomized study  drug using an InteractiveWeb 
Response Sy stem (IWRS). To accomplish random assignments, computer- generated 
randomization lists specified by  [CONTACT_456]'s responsible statistician will be prepared b y 
Randomization Management at the study  sponsor. The randomization lists are provided to an 
IWRS vendor. Before the study  is initiated, the log in information & directions for the I WRS 
will be provided to each site.
The randomization wil l be stratified based on the intended P2Y 12inhibitor use 
(ticagrelor/prasugrel versus clopi[INVESTIGATOR_7745]) after hospi[INVESTIGATOR_2345] .
Study  drug will be dispensed at the study  visits summarized in SoA (Section 1.3). 
Returned study  intervention should not be re -dispensed to the participants.
Patients will be randomly  assigned in a [1:1:1 :1] ratio to receive study  drug. Investigators will 
remain blinded to each participant’s assigned study intervention throughout the course of the 
study . 
Tablets containing 5 mg, 15 mg or 25 mg of BAY 2433334 and corresponding placebo are 
identical in appearance (size, color, shape). In order to maintain the blind study  drugs will be
packed in bottles labeled with a unique number which will be pre -printed on each bottle. In 
addition, participants will be provided with 2 bottles either with active drug or placebo 
depending on the randomization outcome.
6.3.1 Unblinding
The I WRS will be programmed with blind- breaking instructions. In case of an emergency , the 
investigator has the responsibility  for determining if unblinding of a patient’s treatment 
assignment is warranted. If the investigator is unavailable, and a treating physici an not 
associated with the stud y requests emergency unblinding, the emergency unblinding requests 
are forwarded to the study  specific emergency  medical advice 24 hours/[ADDRESS_1239166] the sponsor prior to unblinding a patient’s treatment assignment unless this could delay  emergency  treatment of the patient. If a patient’s treatment assignment is 
unblinded, the sponsor must be notified within [ADDRESS_1239167] be recorded in the source documentation and case report form, as applicable.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  31of 78
BAY 2433334 is known to prolong the activated partial thromboplastin time (aPTT) in a dose 
depended manner. aPTT is a commonly used functional coagulation test widely  used in 
clinic al practi cein patients using anticoagulants and is as well commonly  usedduring acute 
hospi[INVESTIGATOR_602], and as a pre-procedur al screening test. Thus, inadverted unblinding of the 
participant or investigator might take place in cases where aPTT test results are known.
Therefore, the measurement of aPTT during the study conduct is strongl y discouraged and 
should only  be done in case of an (emergency ) situation, where aPTT may  help to guide 
treatment decision. aPTT determinations as part of the study  will not be reported to 
investigator during the study  in order to maintain the b linding. 
6.[ADDRESS_1239168] 
questioning. At each dispensing visit (V6, V8 and V10) and at EoT ( V12) or ET(V12a ) visit, 
compliance will be assessed by  [CONTACT_885738]/capsules. Deviation(s) from the 
prescribed dosage regimen should be recorded in the eCRF.
To monitor compliance, the investigator will be required to document drug dispensing and 
return for each participant . Overall compliance with st udy intervention intake should be 
between 80% and 120% of the scheduled dose at the end of stud y  treatment. The date of 
dispensing the stud y intervention to the participant will be documented. Study  intervention
will be dispensed according to the schedule provided in the SoA (Section 1.3). 
Participants should be instructed to bring all unused study  intervention and empty  packages at 
Visit 6 , 8, 10 andEoT (or ET)visit for accountability  purposes. Any  discrepancies between 
actual and expected amount of returned stud y medication must be discussed with the 
participant the time of the visit, and any  explanation must be documented in the source 
records.
6.5 Prior and Conc omitant Therapy
Any relevant medication or vaccine (including over -the-counter or prescription medicines, 
vitamins, and/or herbal supplements) that the participant is receiving at the time of enrollment or receives during the study  must be recorded along w ith:
Reason for use
Dates of administration including start and end dates
Dosage information including dose and frequency
The Medical Monitor should be contact[CONTACT_43205] y questions regarding concomitant or 
prior therap y.
Special focus needs to be given to  antiplatelet and anticoagulant medications. Any  use in the 
week before the index AMI  event, prior to screening, as well as  concomitant use from study  
entry  until the last scheduled study  visit of the participant, needs to be captured on the 
specified concomitant medication page.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  32of 78
The concomitant use of NSAID therap y during the study is strongl y discouraged since this 
has been shown to increase the risk of gastrointestinal (GI) bleeding. However, if a NSAID 
drug must be temporaril y used, it is r ecommended that the lowest possible dosage for the 
shortest duration possible be selected, not to exceed 4 weeks. Should analgesics be needed, 
use of paracetamol/acetaminophen is recommended . 
Concomitant therap y with any of the following drugs is prohi bited from 14 days (or at least 
five half -lives of the active substance, whatever is longer) before first study intervention 
administration, until at least [ADDRESS_1239169] study  intervention administration:
Strong inhibitors of cy tochrome P450 isoenzy me 3A4 (CYP3A4) e.g. human 
immunodeficiency  virus protease inhibitors (ritonavir, indinavir, nelfinavir, atazanavir, 
or saquinavir), s ystemically  used azole antim ycotic agents (ketoconazole, itraconazole, 
voriconazole, or posaconazole), clarithrom ycin, teli thromy cin
Strong inducers of CYP3A4, e.g. phen ytoin, carbamazepi[INVESTIGATOR_050], phenobarbital, rifampi[INVESTIGATOR_2513], 
or St. John’s wort
A separate complete list with prohibited medications will be provided to the investigator.
6.5.[ADDRESS_1239170] -MI patients, consisting of dual antiplatelet therapy  and later single 
antiplatelet therap y. The choice of P2Y 12inhibitor therap y (ticagrelor, clopi[INVESTIGATOR_885726] ) and duration of treatment with DAPT after hospi[INVESTIGATOR_885727] ,
will be left to the discretion of the treating physician and should follow local standard of care 
guidelines. The use of the antiplatelet background ther apy (ASA and P2Y 12inhibitors) will be 
documented on the e CRF .
6.5.[ADDRESS_1239171] Bleeding During 
the Study
If a participant has serious bleeding during the study  treatment period that requires 
hospi[INVESTIGATOR_059], the following routine measures should be considered:
Temporaril y or permanently discontinue the randomized study  medication .The 
decision to discontinue study drug, temporaril y or permanentl y, will be at the 
discretion of the treating phy sician and must be documented.
Temporaril y discontinue antiplatelet therapi[INVESTIGATOR_014] (aspi[INVESTIGATOR_34251]/or the chosen P2Y 12 
inhibitor) until the bleeding event is sufficientl y controlled , based upon the discretion 
of the treating ph ysician.
Investigate other causes of serious bleeding such as coagulopathies, 
thrombocy topenia, kidney /liver dy sfunction, or other concomitant medications. 
Consider usual supportive treatments for bleeding, including local control of bleeding
through standard procedures based upon the bleeding location , flui d replacement, 
blood transfusion, andfresh frozen plasma (FFP) transfusion. Consideration may also
be given to the use of an antifibrinoly tic agent, such as tranexamic acid or ε -amino 
caproic acid (Tomaselli et al. 2017) . 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  33of 78
If bleeding cannot be controlled by [CONTACT_55874], consider urgent surgical or non -
surgical procedures to stop the bleeding (emergency  surgery , arterial embolization, 
endoscopic cauterization, etc) and unblinding of the randomized t reatment assignment.                
For those participants treated with BAY 2433334, administration of the procoagulants can 
also be considered, but there are no definite data to support the use of these agents.
6.5.[ADDRESS_1239172]  non-cardiac 
surgery or non -cardiac percutaneous/endoscopic procedures 
When possible, non- cardiac surgery  and non- cardiac percutaneous/endoscopic procedures 
should be planned and delayed for at least 24 hours to allow for a 24 -hour washout period 
after temporary  discontinuation of randomized study  drug to mitigate risks of bl eeding.  
For urgent or emergent non- cardiac surgery  or non -cardiac percutaneous/endoscopic 
procedures, when waiting for [ADDRESS_1239173] the urgency  of the procedure based upon the clinical situation. Peri -procedure 
management may  in part, depend on the randomized treatment assignment (BÀY 2433334 or 
placebo) and unblinding of treatment assignment may  be necessary . In general, the treatment 
recommendations should follow the Guidelines for Severe Perioperative Bleeding Management (Kozek -Langenecker SA et al. 2013). The procedure should be conducted in 
such a way  to minimize the risk of bleeding.
Treatment of participants receiving BAY 2433334 during urgent or emergency  non- cardiac 
procedures may  be guided by  [CONTACT_885739] . Apart from giving FXI concentrate (FXI) as replacement therapy  to cover a 
surgical bleeding e vent (Ling et al. 2016 ), there have been reports in the literature about the 
successful use of tranexamic acid or ε -amino caproic acid for the management of these 
patients with a FXI deficiency  when undergoing surgery (Duga and Salomon 2013) . More 
detailed information may be found in the Investigator’s Brochure.
6.5.[ADDRESS_1239174] to be emergently  unblinded if necessary ,to facilitate 
management decisions (e.g. intravenous thromboly sisor intra -arterial thromboly sis in case of 
mechanical clot removal) . 
For particip ants with acute ischemic stroke who are receiving BAY 2433334, the risk of 
bleeding with use of intravenous thromboly sis is unknown and has not been studied; hence a 
clear recommendation in this situation cannot be given. However, it is not recommended tha t 
a thromboly tic agent be given unless it is known that the study  intervention ( BAY 2433334 )
has not been taken in the previous 48 hours, and the aPTT is normal. In this case, the risk of 
bleeding associated with thromboly sis is not expected to be increase d (and unblinding may  
not be necessary ).
For participants who undergo thromboly sis; study  medication should be withheld until at least 
24 hours after thrombolysis.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  34of 78
Mechanical clot removal (thrombectom y) without thrombolysis may  be performed in any
case. 
6.5.5 Guidance for management of participant s who experience a suspected 
new, acute recurrent cardiac ischemic event during the study
Forparticipants who experience a suspected new, acute recurrent cardiac ischemic event 
requiring unplanned hospi[INVESTIGATOR_059] (unstable angina or AMI ), standard of care medications 
should be administered according to local practice guidelines and based upon the chosen 
invasive procedure (dual antiplatelet therap y, if not alread y being used, 
intravenous/subcutaneous anticoagulants, or intravenous antiplatelet therapi[INVESTIGATOR_885735]/IIIa inhibitors or cangrelor).  Study intervention does not need to be
discontinued upon hospi[INVESTIGATOR_55844] a suspected acute recurrent cardiac ischemic event.  Recurrent cardiac ischemic event ( AMI ) endpoint reporting guidelines and processes 
should be followed for these situations.
For pa rticipants who undergo urgent or emergent coronary  angiography  (with or without 
PCI) as treatment for the new recurrent ischemic event, continuation of blinded study  
intervention and concomitant peri-procedural use of standard parenteral or subcutaneous 
anticoagulants (unfractionated heparin, biv alirudin, low molecular weight heparin) during PCI 
is recommended. For participant s who are treated with urgent or emergent CABG surgery , study  drug should be 
stopped (if possible) [ADDRESS_1239175] -surgical drains (chest tubes) have been removed.
The treatment assignment may  have to be emergently  unblinded to facilitate decisions 
regarding treatment with intravenous fibrinol ytics for acute ST- elevation MI. For participant s 
who are receiving B AY 2433334, the risk of bleeding related to the concomitant use of an 
intravenous fibrinol ytic is unknown and has not been studied.  For participants treated with 
intravenous fibrinol ytics, study  drug should be restarted no earlier than 24 hours after 
receiving fibrinol ytics.
6.5.6 Guidance for management of participants who undergo elective 
coronary angiography, PCI, or CABG during the study 
For pa rticipants who undergo elective (scheduled) coronary  angiography , with or without 
elective PCI after randomization or in case of a staged PCI  procedure for the index AMI  event
continuation of blinded study  intervention and concomitant peri-procedural use of standard 
parenteral or subcutaneous anticoagulants (unfractionated heparin, bivalirudin, low molecular 
weight heparin) during PCI  is recommended. For participant s who undergo elective CABG 
surgery  , study  intervention should be temporaril y discontinued for at least [ADDRESS_1239176] -surgical drains (chest tubes) have been removed.
6.6 Dose Modification
This protocol does not allow an y alteration from the outlined dosing schedule (Section 4.3).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  35of 78
6.7 Intervention after the End of the Study
No further stud y intervention is planned following the End of the Study . For the definition of 
“End of Study ” please refer to Section 4.4. 
Any further therapy  at the end of the study  is at the discretion of investigator/treating 
physician.
7. Discontinuation of Study Intervention and Participant 
Discontinuation/W ithdrawal 
7.1 Discontinuation of Study Intervention 
In rare instances, it may  be necessary  for a participant to permanently discontinue (definitive 
discontinuation) study  intervention. If stud y intervention is definitively discontinued, the 
participant will remain in the study  to be evaluated for bleeding and efficacy  outcome events 
until the planned regular end of treatment. See the SoA for data to be collected at the time of 
discontinuation of study  intervention and follo w-up and for an y further evaluations that need 
to be completed.
An ET visit is only  applicable to participants who prematurel y discontinue intake of study 
intervention; such participants should undergo the ET visit as soon as possible ,after 
permanent disc ontinuation of study  intervention .A safet y follow up visit (telephone call) will 
occur 14 day s after the day  of the premature discontinuation of study  intervention (+ 7 day s 
window). If the ET visit falls into the time window for the safet y follow up visit (≥ 2 weeks 
after permanent discontinuation of study  intervention ), a safety  follow up visit will not be 
performed.In this stud y, outcome events and vital status data are crucial to the primary anal ysis and must 
be collected until the end of the study , as pa rticipants will still be part of the study  even if they  
are no longer taking study medication.  Therefore, all efforts will be taken to motivate 
participants to comply  with all study  procedures and to continue to be fol lowed until the end 
of the study for each participant (i.e. 26 to 52 weeks) .
Study  intervention will not be routinely  discontinued in participants reaching a potential 
outcome event or in case of unblinding unless there is a safet y concern or a clear indication 
for an alternative antithr ombotic therapy  as determined by  [CONTACT_16533].
Specificall y, apermanent discontinuation of study  intervention will be required, if 
concomitant treatment with any  of the following medications has to be taken for the 
remaining duration of the stud y conduct :
requirement of full dose and long term anticoagulation therapy  during study  conduct  
(e.g de novo a trial fibrillation, pulmonary  embolism )
strong CYP3A4 inhibitors as well as strong CYP3A4 inducers. 
Discontinuation of study  intervention for ab normal liver function should be considered by  [CONTACT_32845] a participant meets one of the conditions outlined below or if the 
investigator believes that it is in best interest of the participant (please also refer to Section 10.5 for the requirements for liver function monitoring)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  36of 78
ALT or AST >  [ADDRESS_1239177] 
ALT or AST >  [ADDRESS_1239178] for more than 2 weeks 
ALT or AST >  [ADDRESS_1239179] and (total bilirubin > [ADDRESS_1239180] or INR > 1.5 ) 
ALT or AST >  [ADDRESS_1239181] with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and /  or eosinophilia (>  5%) 
See the SoA for data to be collected at the time of premature intervention discontinuation (ie, 
ET visit) and follow- up and for any further evaluations that need to be completed. 
At time of permanent discontinuation of the study  intervention , the particip ant is expected to 
continue regular study  clinic visit sat the investigator’s site as outlined in the protocol.
If this is not possible for any  reason, the investigator and participant must discuss and
determine further follow -up options, as listed below, in descending order of preference :
1.Participant will be contact[CONTACT_55877] -up intervals
2.Participant allows his /her treating ph ysician, e.g. general practitioner or a family  
member ,to be contact[CONTACT_55878]- up interval, 
or at least once at study  end (if allowed in respective country )
3.Participant will be contact[CONTACT_885740] ( Planned 
regular EoT visit for the participant )
After permanent discontinuation of the study  intervention, the following will need to be 
collected at the regular study visits and up to the regular end of treatment visit , preferentiall y 
directly  from the participant and as agreed to b y the participant during the initial informed 
consent process:
Vital Status
Antiplatelet and anticoagulant medications
Outcome events (M I, stroke, death, bleeding , stent thrombosis ).
If a participant is unwilling or unable to return for follow- up visits in person or have follow -
up contacts, sites should col lect as much follow -up visit information as possible, including 
contact[CONTACT_55880]’s representative , famil y member or treating 
physician by [CONTACT_885741]. If applicable, vital status may  be obtained by  [CONTACT_885742]’s medical or public sources (e.g. social media, health insurance, public [death]
registry ), unless this process is not allowed by  [CONTACT_427].
Withdrawal of Consent
Note: None of the above options is considered a withdrawal of consent.
A withdr awal of consent should only  occur in exceptional cases and means that the participant 
does not agree to an y kind of follow -up and specifically  refuses any  further contact [CONTACT_55882] (see Section 7.2)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  37of 78
7.1.1 Temporary Discontinuation 
In case of a temporary  study  medication interruption for an y reason, stud y medication will be 
restarted as soon as medically  justified in the opi[INVESTIGATOR_98236].  There is no defined 
maximum limit for temporary  treatment interruption.  
If study  interventions were temporari lystoppe d, PK/PD blood samples should only  be 
obtained if study  interventions have been restarted and sustained for at least 4 days.
7.2 Participant Discontinuation/Withdrawal from the Study
A participant may withdraw from the study  at an y time at his/her own request, or may  
be withdrawn at an y time at the discretion of the investigator for safet y, behavioral 
compliance, or administrative reaso ns. This is expected to be uncommon.
At the time of discontinuing from the stud y, if possible, an earl y discontinuation visit 
should be conducted, as shown in the SoA. See SoA for data to be collected at the 
time of study  discontinuation and follow -up and for any  further evaluations that need 
to be completed.
The participant will be permanently discontinued both from the study intervention and 
from the study  at that time.
If the participant withdraws consent for disclosure of future information, the sponsor may retain and continue to use any  data collected before such a withdrawal of consent.
At the time of informed consent, participants will be explained all the options to continue in the study  after permanent discontinuation of study  intervention (see 
Section 7.1). This will be re -discussed at the time of permanent discontinuation of 
study  intervention and the pa rticipant’ s specific agreement will be documented. 
Participants will agree to be contact[CONTACT_55883] -up inf ormation should they  
decide to stop the intervention.
When a participant withdraws consent from study  participation before completing the 
study , meaning that the participant does not agree to an y kind of follow -up and 
specificall y refuses an y further contact [CONTACT_44502] , the reason for consent 
withdrawal is to be documented in the source document. Public information can be 
used to obtain vital status for these participants where allowed by [CONTACT_427].
7.[ADDRESS_1239182] to follow- up if he or she repeatedl y (twice) fails to return 
for scheduled visits and is unable to be contact[CONTACT_17066]. 
The following actions must be taken if a participant fails to return to the clinic for a required 
study  visit:
The site must attempt to contact [CONTACT_221728]/or should continue in the study .
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  38of 78
Before a participant is deemed lost to follow up, the investigator or designee must 
make every  effort to regain contact [CONTACT_6635] (where possible, 3 telephone 
calls and, if necessary , a certified letter to the participant’s last known mailing address 
or local equivalent methods). These contact [CONTACT_13140]’s medical record.
Should the participant continue to be unreachable, he/she will be conside red lost to 
follow up.
In order to reduce risk for lost to follow -up the site should collect [ADDRESS_1239183] information of the participant ’s children, 
caretaker, legal represen tative, or primary  physician. The correctness of these contact 
[CONTACT_885743] y at the stud y visits.
A patient locator service may be used to re -establish contact [CONTACT_4490] a pa rticipant in case 
the site has exhausted a ll means of regaining c ontact, if the pa rticipant will agree to 
this in the ICF.
8. Study Assessments and Procedures
Study  procedures and their timing are summarized in the SoA (Section 1.3). Protocol 
waivers or exemptions are not allowed.
Immediate safety  concerns should be discussed with the sponsor immediately  upon 
occurrence or awareness to determine if the participant should continue or discontinue study  intervention.
Adherence to the stud y design requirements, including those specified in the SoA, is 
essential and required for study conduct.
All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility  criteria. The investigator will maintain a screening log 
to record details of all participants screened and to confirm eligibility  or record 
reasons for screening failure, as applicable. 
Procedures conducted as part of the participant’s routine clinical management (e .g., 
blood count) and obtained before signing of the ICF may  be utilized for screening or 
baseline purposes provided the procedures met the protocol- specified criteria and were 
performed within the time frame defined in the SoA.
8.1 Efficacy Assessments 
The efficacy  assessments i nclude primary  and secondary  endpoints of the study (seeSection 
3).
8.1.1 Primary Efficacy Endpoint
The primary  efficacy  endpoints of the study  include the anal ysis of a composite of:
CV death
MI
Stroke (ischemic and hemorrhagic)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  39of 78
Stent thrombosis
A definition of the primary  efficacy  outcome events is provided as follows and further 
specified in the charter of the clinical event committee (CEC). Details on the time periods for 
collecting Outcome Events information are reported in Section 10.8.
[IP_ADDRESS] Cardiovascular Death
Cardiovascular death includes death due to stroke, my ocardial infarction, heart failure or 
cardiogenic shock, sudden death or any other death due to other cardiovascular causes.  In 
addition, death due to non- traumatic hemorrhage will be included.
[IP_ADDRESS] Myocar dial Infarction
The term acute m yocardial infarction (MI) is used when there is evidence of myocardial 
necrosis in a clinical setting consistent with acute my ocardial ischemia. According to the M I 
Universal Definition from 2018 ( Thygesen et al. 2018 ) the diagnosis of MI requires the 
combination of:
Presence of acute my ocardial injury  (changes in cardiac biomarkers) and
Evidence of acute m yocardial isc hemia derived from the clinical presentation, 
electrocardiographic changes, or the results of m yocardial or coronary  artery imaging, 
or in case of post -mortem pathological findings irrespective of biomarker values .
Five t ypes of m yocardial infarction can be differentiated:
Type 1 Spontaneous my ocardial infarction
Type 2 M I secondary  to an ischemic imbalance
Type 3 M I resulting in death when biomarker values are unavailable
Type 4a MI related to percutaneous coronary  intervention (PCI ) 
Type 4b M I related t o stent thrombosis
Type 4c MI related to re -stenosis associated with PCI
Type 5 M I related to coronary  artery  by[CONTACT_15806] (CABG)
[IP_ADDRESS] Stroke   
Stroke is defined as an acute epi[INVESTIGATOR_55845] d ysfunction caused b y an 
injury  of the brain, spi[INVESTIGATOR_1831], or retina as a result of hemorrhage or infarction.
Differentiation is made regarding ischemic stroke and hemorrhagic stroke.
Hemorrhagic stroke is defined as an acute, atraumatic extravasation of blood into the brain 
parench yma, intrave ntricular, or subarachnoid space with associated neurological sy mptoms. 
This does not include microbleeds nor hemorrhagic transformation of an ischemic stroke. 
An ischemic stroke is defined as rapid onset (or presence on awakening) of a new focal 
neurolog ical deficit with clinical ( ≥ 24 hours s ymptoms / signs) or imaging evidence of 
infarction that is not attributable to a non -ischemic cause (i.e. not associated with infection, 
tumor, seizure, severe metabolic disease). 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  40of [ADDRESS_1239184] for 
24 hours (or death if occuring before 24 hours) but without neuroimaging or autopsy .
[IP_ADDRESS] Stent Thrombosis
Uniform definitions have been developed and were updated by [CONTACT_850103] -2(ARC -2), incorporating diagnostic certainty as well as timing 
Definition Based on Diagnostic Certaint yof Stent Thrombosis (ST) ( Garcia -Garcia et al. 
2018):
“Definite” ST :The highest level of certainty . Either angiographic or pathological 
confirmation of stent thrombosis. 
“Probable” ST :Regardless of the time after the index procedure, an y myocardial 
infarction that is related to documented acute ischemia in the territory  of the implanted 
stent without angiographic confirmation of stent thrombosis and in the absence of an y 
other obvious cause
In this tri al the categories of  “probable” ST are excluded and onl y “definite” ST is selected as 
endpoint.
Definition Based on Timing of Stent Thrombosis (ST):
Acute ST*: 0 to 24 hrs after stent implantation
Subacute ST*: >24 hours to 30 day s after stent implantatio n
Late ST: >30 day s to 1 year after stent implantation
Very  late ST: >1 year after stent implantation
*Acute or subacute can also be summarized under the term early  stent thrombosis
(0 to 30 day s).
8.1.2 Secondary Efficacy Endpoint
The secondary efficacy  endpoi nts of the study  include the individual components of the CV 
death, MI, stroke , stent thrombosis and all cause mortality .
A definition of the efficacy  outcome events is provided in Section 8.1.1 and further specified 
in the Clinical Event Committee Charter.
8.2 Safety Assessments 
The safet y assessments include primary , secondary  and exploratory endpoints of the study . At 
each visit during the study as specified in the SoA, the investigator will evaluate the 
participant for the occurrence of bleeding events. All necessary  information to classify  
bleeding events according to the ISTH, the Thromboly sis In M yocardial Infarc tion (TIM I) 
and the Bleeding Academic Research Consortium (BARC) criteria will be collected in the CRF.  
8.2.1 Primary and Secondary Safety Endpoints
Primary Safety Endpoints
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  41of 78
Bleeding Academic Research Consortium (BARC) definition type 2, 3 and 5 as 
defined b y the (Section [IP_ADDRESS])
Secondary Safety Endpoints
all bleeding
BARC bleeding definition t ype 3, 5
BARC bleeding definition t ype 1, 2, 3, 5
[IP_ADDRESS] BARC Bleeding Definition
The BARC bleeding definition encompasses the following bleeding t ypes ( type 4: CABG-
related bleeding is not applicable to this study ):
Type 0: no bleeding
Type 1: bleeding that is not actionable and does not cause the patient to seek 
unscheduled performance of studies, hospi[INVESTIGATOR_059], or treatment b y a healthcare 
professional; may  include epi[INVESTIGATOR_15664]- discontinuation of medical therap y 
by [CONTACT_15743] a healthcare professional
Type 2: any  overt, a ctionable sign of hemorrhage (e.g. more bleeding than would be 
expected for a clinical circumstance, including bleeding found b y imaging alone) that 
does not fit the criteria for ty pe 3, or [ADDRESS_1239185] one of the following 
criteria: (1) requir ing nonsurgical, medical intervention by  a healthcare professional, 
(2) leading to hospi[INVESTIGATOR_3820], or (3) prompting evaluation
Type 3:
Type 3a
Overt bleeding plus hemoglobin drop of 3 to <  5 g/dL* (provided 
hemoglobin drop is re lated to bleed)
Any transfusion with overt bleeding
Type 3b
Overt bleeding plus hemoglobin drop ≥ 5 g/dL* (provided hemoglobin drop 
is related to bleed)
Cardiac tamponade
Bleeding requiring surgical intervention for control (excluding 
dental/nasal/skin/hemorrhoid)
Bleeding requiring intravenous vasoactive agents
Type 3c
Intracranial hemorrhage (does not include microbleeds or hemorrhagic
transformation, does include intraspi[INVESTIGATOR_1304]) ; subcategories confirmed b y 
autopsy  or imaging or lumbar p uncture
Intraocular bleed compromising vision
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  42of 78
Type 5: fatal bleeding
Type 5a
Probable fatal bleeding; no autopsy  or imaging confirmation but clinically  
suspi[INVESTIGATOR_55847] 5b
Definite fatal bleeding; overt bleeding or autopsy  or imaging confirmation
*Correcte d for transfusion (1 U packed red blood cells or 1 U whole blood=1g/dL
  hemoglobin)
8.2.2 Exploratory Safety Endpoints
The exploratory  safet y endpoints include the analysis of the following outcome events:
TIMIclinical lysignificant bleeding
TIMI major bleeding
TIMI minor bleeding
ISTH major and clinical relevant non -major bleeding
ISTH major bleeding
[IP_ADDRESS] TIMI Bleeding Definition
The non- CABG related TI MI clinicall y significant bleeding definition encompasses the 
following bleeding t ypes excluding events that are related to a CABG procedure:
TIMI Major Bleeding
Any symptomatic intracranial hemorrhage
Clinically  overt signs of hemorrhage (including imaging) associated with a 
drop in hemoglobin of ≥ 5 g/dL (or when the hemoglobin concentration 
was not availa ble, an absolute drop in hematocrit of ≥  15%).
Fatal bleeding (bleeding that directly  results in death within 7 day s)
TIMI Minor Bleeding
Any clinically  overt sign of hemorrhage (including imaging) that was 
associated with a fall in hemoglobin concentratio n of 3 to <  5 g/dL  (or, 
when hemoglobin concentration was not available, a fall in hematocrit of 
10 to <  15%).
TIMI Bleeding Events Requiring Medical Attention
Any bleeding event that required medical treatment, surgical treatment, or 
laboratory  evaluation and did not meet criteria for a major or minor 
bleeding event, as defined above.
In addition to TI MI significant bleeding also TI MI major bleeding and TIMI  minor bleeding 
will be anal yzed(Chesebro e t al. 1987).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  43of 78
[IP_ADDRESS] ISTH Major Bleeding
An event that meets at least one of the below criteria for a major bleeding event according to 
the definition given b y the I STH:
Fatal bleeding, and/or
Symptomatic bleeding in a critical area or organ (intracranial, intraocular, intraspi[INVESTIGATOR_1304], 
pericardial, retroperitoneal, intraarticular, or intramuscular with compartment syndrome), and/or 
Clinically  overt* bleeding associated with a recent decrease in the hemoglobin level of 
≥ 2 g/dL  (20 g/L; 1.24 mmol/L) compared to the most recent hemoglobin value available before the event, and/or 
Clinically  overt* bleeding leading to transfusion of 2 or more units of packed red 
blood cells or whole blood
*overt bleeding requires the identification of the bleeding location and the hemoglobin drop 
and/ or transfusion needs to be related to the bleeding
[IP_ADDRESS] ISTH Clinically Relevant Non- Major Bleeding
Clinically  relevant non- major bleeding is considered an y sign or sy mptom of hemorrhage that 
does not fit the criteria for the ISTH definition of major bleeding, but does meet at least one of the following criteria (Kaatz et al. 2015):
requiring medical inte rvention by  a healthcare professional
leading to hospi[INVESTIGATOR_3820]
prompting a face to face (i.e. not just a telephone or electronic communication) 
evaluation
8.2.3 Physical Examinations
Height and weight (also referred to as biometrics in the SoA) will be measured and 
recorded at screening (see Section 1.3).
8.2.4 Vital Signs
Blood pressure and pulse measurements will be assessed with a completel y automate d 
device. Manual techniques will be used only if an automated device is not available.
Blood pressure and pulse measurements should be preceded b y at least [ADDRESS_1239186] for the participant in a quiet setting without distractions (eg, television, cell 
phones).
Vital signs will be measured in a semi- supi[INVESTIGATOR_55848] [ADDRESS_1239187] and will 
include sy stolic and diastolic blood pressure, and pulse 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  44of 78
8.2.5 Electrocardiograms
A single12 -lead ECG will be obtained as outlined in the SoA (see Section 1.3 ) using 
an ECG machine that automatically  calculates the heart rate and measures PR, QRS, 
QT, and QTc intervals. 
8.2.6 Clinical Safety Laboratory Assessments
See Section 10.[ADDRESS_1239188] of clinical laboratory tests to be performed and to the SoA 
for the timing and frequency . 
The investigator must review the labo ratory  report, document this review, and record 
any clinically  relevant changes occurring during the study  in the AE section of the 
CRF. The laboratory  reports must be filed with the source documents. Clinically  
significant abnormal laboratory findings are those which are not associated with the 
underly ing disease, unless judged b y the investigator to be more severe than expected 
for the participant's condition.
All laboratory  tests with values considered clinically  significantl y abnormal during 
participati on in the study  or within [ADDRESS_1239189] dose of stud y intervention 
should be repeated until the values return to normal or baseline or are no longer 
considered clinically  significant by  [CONTACT_55886] .
oIf such values do not return to normal/baseline within a period of time judged reasonable b y the investigator, the etiology should be identified and the sponsor 
notified.
oAll protocol -required laboratory  assessments, as defined in Section 10.2, must be 
conducted in accordance with the laboratory  manual and the SoA. 
oIf laboratory  values from non -protocol specified laboratory  assessments 
performed at the institution’s local laboratory require a change in participant management or are considered clinically  significant by  [CONTACT_093] (eg, SAE 
or AE or dose modification), then the results must be recorded in the CRF. 
8.[ADDRESS_1239190] (AESI) for the study are specified in Section 8.3.7
AEs that are outcome events according to the study protocol are further described in Section 
8.3.6 and Section 10.3.5.
AEswill be reported b y the participant (or, when appropriate, b y a caregiver, surrogate, or the 
participant's legall y authorized representativ e).
The investigator and an y qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE . They remain responsible for 
following up SAEs or AEs considered related to the study  intervention or those that caused 
the participant to discontinue th e study  intervention and/or study . AESI s have to be followed 
up regardless of causality or relationship to the study  intervention.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  45of 78
8.3.1 Time Period and Frequency for Collecting AE and SAE Information 
All SAEs will be collected from the start of intervention (firstday of study  intervention 
intake )until the safet y follow -up visit at the time points specified in the SoA (Section 1.3).
All AE will be collected from the start of intervention until the safety  follow -up visit at the 
time points specified in the SoA (Section 1.3).
Medical occurrences that begin before the start of study  intervention but after obtaining 
informed consent will be recorded on the Medical History /Current Medical Conditions 
section of the case report form (CRF) not the AE section.
All SAEs will be recorded and reported to the sponsor or designee immediately and under no 
circumstances should this exceed 24 hours after the investigator becomes aware of this event , 
as indicated in Section 10.3 . The investigator will submit any  updated SAE data to the 
sponsor within 24 hours of it being available.Investigators are not obligated to activel y seek AE or SAE after conclusion of the study 
participation. However, if the investigator learns of an y SAE, including a death, at an y time 
after a participant has been discharged from the study , and he/she considers the event to be 
reasonabl y related to the study  intervention or study  participation, the investigator must 
promptly  notify  the sponsor. 
8.3.2 Method of Detecting AEs and SAEs
The method o f recording, evaluating, and assessing causality of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Section 10.3.
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open -ended and 
non leading verbal questioning of the participant is the preferred method to inquire about AE 
occurrences. 
8.3.3 Follow-up of AEs and SAEs
After the initial AE/SAE r eport, the investigator is required to proactivel y follow each 
participant at subsequent visits/contacts. All SAEs, and serious and non- serious AEs of 
special interest (as defined in Section 8.3.7), will be followed until resolution, stabilization, 
the event is otherwise explained, or the participant is lost to follow -up (as defined in Section 
7.3). Further information on follow -up procedures is provided in Section 10.3. 
8.3.4 Regulatory Reporting Requirements for SAEs
Prompt notification by  [CONTACT_11012] a nSAE is essential so that 
legal obligations and ethical responsibilities towards the safet y of participants and the 
safet y of a stud y intervention under clinica l investigation are met. 
The sponsor has a legal responsibility  to notify  both the local regulatory  authority  and 
other regulatory  agencies about the safet y of a study  intervention under clinical 
investigation. The sponsor will comply  with country -specifi c regulatory  requirements 
relating to safet y reporting to the regulatory  authority , Institutional Review Boards 
(IRB)/Independent Ethics Committees (I EC), and investigators.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  46of 78
For all studies except those utilizing medical devices, investigator safet y report s must 
be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to 
local regulatory  requirements and sponsor policy  and forwarded to investigators as 
necessary .
An investigator who receives an investigator safety report describing a nSAE or other 
specific safet y information (e .g., summary  or listing of SAEs) from the sponsor will 
review and then file it along with the Investigator’s Brochure and will notify  the
IRB/IEC, if appropriate according to local requirements.
8.3.5 Pregnancy
Detail s of all pregnancies in female participants and, if indicated, female partners of 
male participants will be collected after the start of study  intervention and until [ADDRESS_1239191] dose intake.
If a pregnancy  is reported, the investigator should inform the sponsor within 24 hours 
of learning of the pregnancy  and should follow the procedures outlined in Section 
10.4.
Abnormal pregnancy  outcomes (e .g., spontaneous abortion, fetal death, stillbirth, 
congenital anomalies , ectopic pregnancy ) are considered SAEs.
8.3.6 Disease-Related Events  
During the study  there will be incidences where AEs are also potential efficac y or safet y 
endpoints.
In compliance with applicable regulations, in the event of a S[LOCATION_003]R (see Section 8.3.4) 
related to the blinded treatment, the pa rticipant ’s treatment code will usually  be unblinded 
before reporting to the health authorities. Notifications of ethic committees and investigators 
will be done according to all applicable regulations (see Section 10.3.4).
The following disease -and treatment -related events are common in participants with acute 
myocardial infarction who are being treated with an anticoagulant:
a.Bleeding
b. D eath 
c.Myocardial Infarction 
d. Ischemic stroke
e.Stent thrombosis
These events will be recorded on the corresponding CRF page in the participant’s CRF.
These events will also be monitored and adjudicated by a Central Event Committee (CEC) on 
an ongoing basis.In addition, these events require reporting to the sponsor according to the standard process of 
expedited reporting of SAEs within 24 hours of the investigator’s awareness of the event, along the timelines set for reporting of SAEs and AESI s.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  47of 78
However, due to their expectedness, efficacy  endpoints lis ted above (b-e : death, my ocardial 
infarction, ischemic stroke , and stent thrombosis ), including events indicative of those 
outcome events ( e.g. TI A, cardiac ,chest pain) will not be subject to sy stematic unblinding 
and expedited S[LOCATION_003]R reporting to health authorities.
8.3.[ADDRESS_1239192] (AESIs) will be all AEs related to hepato -biliary  
dysfunction , i.e. relevant increases in the respective liver lab values ( ALT >  [ADDRESS_1239193]  > 3 x UL N with confirmatory  re-testing within 5 day s of initial lab value elevation), see 
Section 10.5, with or without sy mptoms such as e.g. nausea, vomiting, right upper quadrant 
abdominal pain, fatigue, weakness, weight loss and jaundice. Re-testing of lab values can be 
performed at the loca l lab and needs to be documented in the CRF.
AESIshave to be reported to the sponsor within 24 hours of the investigator’s awareness , i.e. 
along the timelines set for SAEs (even though they may  not be classified as serious), as 
described in Section 8.3.1 .
8.4 Treatment of Overdose
For this study , any  dose of BAY 2433334 greater than 3 assigned dail y doses (i.e. more than 6 
tablets) within a 24- hour time period will be considered an overdose.
The s ponsor does not recommend specific treatment for an overdose of BAY 2433334, as a 
specific antidote for the study  drug is not available. The use of activated charcoal to reduce 
absorption may  be considered.
Due to the mechanism of action, an overdose of the study  drug could potentially  result in 
hemorrhage. In case of bleeding linked to overdose the guidance on bleeding management as 
found in Section 6.5.2 should be followed . 
In the event of an overdose, the investigator/treating ph ysician should:
1. Contact [CONTACT_27465] .
2. Closely  monitor the participant for an y AE/SAE and laboratory  abnormalities until 
study  drug can no longer be detected sy stemically  (at least 5 day s.).
4. Document the quantit y of the excess dose as well as the duration of the overdose in the 
CRF.
Decisions regarding dose interruptions or modifications will be made by  [CONTACT_20616] r in 
consultation with the Medical Monitor based on the clinical evaluation of the participant.
8.5 Pharmacokinetics
For the investigation of systemic exposure to BAY 2433334 and its relationship with treatment effects, the plasma concentrations of BAY 2433334 and optionally  of its metabolite 
M-10 (BAY 2826102) will be determined at different time points using a sparse sampling 
approach in all participating participants. Details about the collection, processing, storage and shipment of samples will be provided separatel y (e.g. in the Laboratory  Manual). Study  
personnel responsible for bioanaly ticswill be unblinded and will have access to the 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  48of [ADDRESS_1239194]. Analy sisof samples from participants not treated with BAY 2433334 is 
optional. 
Blood samples will be collected at the time points indicated in the SoA (Section 1.3). PK 
samples obtained at additional time points based on the investigator’s discretion will not 
qualify  as a protocol deviation and will be used for PK analy sis as well. Deviations from the 
specified sampling intervals will be documented and taken into account for the PK anal ysis. 
Date and time of the PK sample collection and date and time of most recent study  intervention 
intake ( ie, both of the PK/PD sampling day , and of the day  before that ) must be documented.
At Visit [ADDRESS_1239195] -dose samples will be taken as indicated in the SoA (Section 1.3)
The PK data and the relationship of the BAY 2433334 exposure parameters (e.g. C max, AUC) 
with treatment effects might be evaluated using population approaches (e.g. non -linear mixed 
effect modeling) including potential influence of relevant participant co-variables. Anal ysis 
and report will be done under a separate cover. This evaluation might be started prior to database lock: if this is applicable, appropriate measures will be taken to maintain blinding of the study  team. 
PK samples will be anal yzed, using validated analy tical methods. Quality  control (QC) and 
calibration samples will be anal yzed concurrently with study  samples. The results of 
calibration samples and QC samples will be reported in the Bioanal ytical Report which will 
be included in the CSR for this study .
8.6 Pharmacodynamics
Blood sampling for PD parameters is scheduled for the time points as given in Section 1.3. 
The actual date and time of blood sampling will be documented in the CRF. AllPDparameters will be measured using validated methods.
Quality  control and calibration samples will be analy zed c oncurrently  with study  samples. For 
selected PD parameters , the results of QC samples will be reported together with analy te 
concentrations in the Clinical Study  Report of this study .
Concentrations of the analy te are calculated according to the method des cription. Detailed 
method descriptions of all PD methods will be filed with the study  report.
The following parameters will be used to assess the PD effects after administration of the investigational drug , but will be performed optionally  and/or onl y in a subset of participants:
aPTT will be measured using a coagulation assay via kaolin -trigger
Activated Facto r XIa activity  (AXIA) will be analy zed using a kaolin -trigger and a 
fluorogenic substrate readout
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  49of 78
D-Dimer will be measured using an immunoturbidometric method
FXI concentration will be measured via ELISA using pol yclonal antibodies
Fibrinogen will be measured using a coagulation assay
Factor XII activity  will be assessed with an aPTT -based coagulation test using FXII-
deficient plasma. Factor XII concentration will be anal yzed using an enzyme -linked 
immunosorbent assay  (ELISA).
vWF antigen level and vWF ristocetin cofactor (i.e. vWF functional activity ) will be 
analyzed using turbidometric assays.
The study  sponsors reserve the right not to conduct all or part of the above mentioned 
analysis.
In addition, blood samples will be taken for exploratory  biomarker work (see Section 8.8).
Detailed information about the collection, processing, storage and shipment of the samples 
will be provided separately  (e.g. sample handling sheets and / or laboratory manual).
8.7 Genetics
Genetic as well as non -genetic analy ses will be part of the biomarker investigations in this 
study . See Section 8.8 for details.
8.8 Biomarkers
Exploratory biomarker analy ses (scheduled for the time points as given in Section 1.3), that 
might be performed optionally  and/or onl y in a subset of patients are:
NT-proBNP will be measured using an electrochemi luminescence immuno assay  
(ECLIA)
hsCRP will be measured using an immunoturbidometric method
Thrombin- activatable fibrinoly sis inhibitor (TAFI) and C1 inhibitor activity will be 
measured using chromogenic substrate assay s
TAT and F1.2 will be analy zed using immunoassay s
In addition to the biomarkers described above , further biomarkers related to the mode of 
action or the safet y of BAY 2433334 and similar drugs may  be examined. The same applies 
to further biomarkers deemed r elevant to cardiovascular diseases and associated health 
problems. These investigations may  include e.g. diagnostic, safet y,PD, monitoring, or 
potentially  predictive biomarkers. 
Those additional anal yses may  include genetic as well as non- genetic biomark ers. Genetic 
investigations may  be of any  kind, except for whole genome sequencing. Results will be 
reported under separate cover, if the evaluations are performed.
Details on the collection, processing, storage, and shipment of biomarker samples will be 
provided in separate documents (e.g., sample handling sheets or lab manual). Samples may  be 
stored for a maximum of 15 y ears (or according to local regulations) following the end of the 
study  at a facilit y selected by [CONTACT_55888].
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  50of 78
8.9 Immunogenicity Assessment
Not applicable .
8.10 Health Economics/Medical Resource Utilization and Health Economics
Health Economics/Medical Resource Utilization and Health Economics parameters are not 
evaluated in this study . 
9. Statistical Considerations 
9.1 Statistical Hypotheses
The aim of the study is to estimate the incidence of MACE and bleeding events of BAY 2433334 and compare it with the incidence of placebo.
No formal h ypothesis testing is planned in this study.
9.2 Sample Size Determination 
Approximatel y 1650 participants will be screened to achieve 1600 randomly  assigned to study  
intervention for an estimated total of 400 evaluable participants per intervention group.
With a sample size of 400 participants per treatment arm, an incidence risk for a prim ary 
safet y event of 4.5% at Day 180 for all treatment arms, and a proportion of about 5% of the 
randomized participants not contributing post-randomization information about the 
occurrence of primary bleeding events, it is expected that about [ADDRESS_1239196] 
experienced a primary  safety  outcome until Day  180.
With 70 participants with a primary  bleeding event and an observed HR of 1.0 for the 
comparison of BAY 2433334 (all doses pooled) to placebo, the upper bound of the 2 -sided 
90% CI  for the HR will be approximately  1.44. If the true HR is 1.0 the power to observe a 
2-sided 90% CI for the HR below 1.82 is 80%.
9.3 Populations for Analyses 
For purposes of analy sis, the following populations are defined:
Population Description
Enrolled All participants who sign the ICF
Full Analysis Set All participants randomized to study drug.
Safety Set All participants randomly assigned to study drug and who take 
at least [ADDRESS_1239197] 1 valid 
plasma concentration and without protocol deviation, which 
would interfere with the evaluation of the PK data.
Abbreviations: ICF = Informed consent form, PK = pharmacokinetic(s)
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  51of 78
The primary  and secondary  safet y endpoints will be anal yzed using the S afety  Set. The 
analysis of the full anal ysisset will be used as a supportive anal ysis. Pharm acokinetic and 
pharmacod ynamic data will be anal yzed using the Pha rmacokinetic anal yses set.
9.4 Statistical Analyses
9.4.1 Gerenal considerations
The statistical anal ysis plan (SAP) will be developed and finalized before database lock and 
will describe the participant populations to be included in the anal yses, and pr ocedures for 
accounting for missing, unused, and spurious data. This section is a summary of the planned 
statistical analy ses of the primary  and secondary  endpoints and estimands.
The aim of this study  is to gain knowledge of the safet y profile and the efficacy  of 
BAY 2433334.
For the intercurrent event “discontinuation of study  treatment” the “treatment policy ” strategy  
is chosen for efficacy estimands and the “while on treatment” strategy  is chosen for safet y 
estimand s.
The intercurrent event Death will be handled with the while alive strategy .
Confidence intervals will be two sided 90% - confidence intervals.
Time to event variables will be anal yzed using Kaplan-Meier estimates of cumulative risk and 
cumulative hazard functions. The hazard ratios an d the corresponding confidence intervals 
will be estimated on separate Cox proportional hazard models for each comparison. No comparison of the different doses of BAY [ADDRESS_1239198] occurrence. The 
incidence risk for outcome events will be estimated separatel y for the doses of BAY 2433334 
and/or for the pooled doses and/or the 20 and 50 mg doses combined and compared to 
placebo.The bleeding risk of BAY 2433334 (all doses po oled) as compared to placebo will be 
estimated using the Cox proportional hazards model.Main Data scope for safety  of the trial is the treatment emergent data scope, counting all 
events from first intake of study  drug until [ADDRESS_1239199] study  drug intake.
The efficacy  of BAY 2433334 ( 20 and 50 mg pooled) as compared to placebo will be 
estimated using the Cox proportional hazards model.Main Data scope for efficacy  of the trial is the ITT data scope, counting all events from 
randomization until end of study
All time-to-event anal yses will be stratified by[CONTACT_587583] P2Y
12inhibitor use 
(ticagrelor/prasugrel versus clopi[INVESTIGATOR_7745]) if not mentioned different.
All collected events will be anal yzed descriptively, using methods like frequency  tables and 
others.The statistical anal yses will be performed using SAS; the version used will be specified in the 
statistical analy sis plan (SAP).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  52of 78
9.4.2 Primary endpoints
Efficacy analysis
The primary  efficacy  estimand is: The hazard ratio of the composite of CV death, MI, strok e 
and stent thrombosis comparing BAY 2433334 (20 and 50 mg pooled) with placebo in adult 
participants with an AMI treated with DAPT while alive and regardless of treatment 
discontinuation.
The primary  efficacy  estimator will be the hazard ratio from a Cox proportional hazards 
model comparing BAY 2433334 (20 and 50 mg pooled) with placebo. The estimation will be 
performed on the full analy sisset and the ITTdata scope.
As sensitivity  anal yses the estimation on the Safety set and the treatment emerge ntdata scope 
will be performed .
In addition, incidence proportions for the primary efficacy  endpoint will be reported.
Safety Analyses
The primary  safet y estimand is: The hazard ratio of BARC ty pe 2, [ADDRESS_1239200] ratio from a Cox proportional hazards model 
comparing BAY 2433334 (all doses pooled) with placebo. The estimation will be performed 
on the safet y set and the treatment emergent data scope.
As sensitivity  anal yses the estimation on the full analy sisset and the ITT data scope will be 
performed.In addition, incidence proportions for the primary safet y endpoint will be reported.
9.4.3 Secondary endpoints
Efficacy analysis
The second ary efficacy  estimand sare: The hazard ratio of <individual endpoint >of 
comparing BAY 2433334 (20 and 50 mg pooled) with placebo in adult participants with an 
AMI treated with DAPT while alive and regardless of treatment discontinuation
For each of the individual enpoints:
All cause mortalit y
CV death
MI
stroke (ischemic and h emorrhagic) 
stent thrombosis
Safet y analysis
The second ary safet y estimand sare: The hazard ratio of <individual endpoint> comparing 
pooled BAY 2433334 with placebo in adult participants with an AMI treated with DAPT and 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  53of [ADDRESS_1239201] one dose of study medication of BAY 2433334 or placebo and while 
the patient is alive and exposed to study  drug
For each of the individual enpoints:
all bleeding
BARC bleeding definition Ty pe 3, 5
BARC bleeding definition Ty pe 1, 2, 3, 5
9.4.4 Tertiary/exploratory endpoints
Exploratory  safety  endpoints are:
TIMIclinical lysignificant bleeding
TIMI major bleeding
TIMI minor bleeding
ISTH major and clinical relevant non -major bleeding
ISTH major bleeding
The anal yses of these endpoints will be specified in the SAP.
9.4.5 Other Safety Analyses 
Adverse Events (AE) will be anal yzed by [CONTACT_9086], such as frequency tables. All 
AEs will be tabulated according to the affected s ystem organ class and preferred term, as 
coded by [CONTACT_885744] (MedDRA).
9.4.6 Other Analyses 
PK, pharmacod ynamic, and biomarker exploratory anal yses will be described in the statistical 
analysis plan finalized before database lock. The population PK analy sis will be presented 
separately  from the main clinical study  report (CSR). 
9.[ADDRESS_1239202] part y, i.e. the 
statistical analy sis center (SAC) that supports the IDMC and thus, is independent of the study  
team and the sponsor . A small group of academic leaders (Executive Committee) including 
the heads of the three Steering Committees that have been established for the individual 
studies and sponsor representatives will participate in the review of these data. IDMC members will also be included in this review. The data will be kept strictly  confidential by  
[CONTACT_885745] .Thus, the study  integrit y 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  54of [ADDRESS_1239203] interim a nalysis will be conducted once about 50% of the participants (800 
participants) with a minor non- cardioembolic ischemic stroke (NIHSS ≤ 7) are enrolled in the 
study  [ADDRESS_1239204] 12.5% of participa nts (200 
participan ts). If the review confirms the safet y profile of BAY 2433334 and raises no concern 
regarding (intracranial) hemorrhage or hemorrhagic transformation of the ischemic stroke, 
Part B of the stud y [ZIP_CODE] will be initiated, during which from then on participants with more 
severe cases of stroke (NIHSS ≥  8 and ≤ 15) can also be included as well as participants after 
thromboly sis or endovascular therap y (mechanical thrombectomy ). Even though the primary  
focus for this interim analy sis is specific for the decision for the stroke study [ZIP_CODE] onl y, data 
and especially  bleeding data from this study  and study19765 will be taken into consideration.  
The second interim anal ysis will occur when sufficient data are available from all three Phase 
2 studies. This interim ana lysis may  occur, when approximately  80% of all planned 
participants, taken all three studies together, are randomized. This meeting will aim to assess 
whether the interim data support decision making on dose and design for a potential Phase [ADDRESS_1239205] dose (in case of an 
unexpected higher bleeding rate in the highest dose or in the combination with antiplatelet 
therap y) or addition of a lower or higher dose or replacement of one dose (in case of  a 
difference in pharmacokinetics or PD paramete rs such as inhibition of FXIa in the patient 
populations compared to healthy  volunteers).
9.6 Independent Data Monitoring Committee (IDMC)
An independent data monitoring committee (IDMC) will be involved in the review of the safet y data for stud y [ZIP_CODE] , and of the overall safety  data across all three Phase 2 studies with 
BAY 2433334 (Section [IP_ADDRESS]). Detailed information on the roles and responsibilities of the IDMC wil l be described in the IDMC Charter.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  55of 78
10. Supporting Documentation and Operational Considerations
10.1 Appendix 1: Regulatory, Ethical, and Study Oversight Considerations
10.1.1 Regulatory and Ethical Considerations
This study  will be conducted in accordance with the protocol and with the following:
 Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical 
Sciences (CIOMS) International Ethical Guidelines
 Applicable ICH Good Clinical Practice (GCP) Guidelines
 Applicable laws and regulations
The protocol, protocol amendments, I CF, Investigator Brochure, and other relevant 
documents (eg, advertisements) must be submitted to an I RB/IEC by  [CONTACT_55892]/IEC before the study  is initiated. 
Any amendments to the protocol will require IRB/I EC approval before 
implementation of changes made to the stud y design, except for changes necessary to 
eliminate an immediate hazard to study  partici pants. Any substantial modifications of 
the protocol will be submitted to the competent authorities as substantial amendments for approval, in accordance with ICH Good Clinical Practice and national and international regulations.
The investigator will be responsible for the following:
 Providing written summaries of the status of the study  to the IRB/IEC annually  
or more frequentl y in accordance with the requirements, policies, and procedures 
established by  [CONTACT_1201]/IEC
 Notify ing the IRB/IEC of SAEs or other significant safet y findings as required 
by [CONTACT_1744]/IEC procedures
 Providing oversight of the conduct of the stud y at the site and adherence to 
requirements of 21 CFR, ICH guidelines, the IRB/IEC, European regulation 
536/2014 for clinical studies (if applicable ), and all other applicable local 
regulations
10.1.2 Financial Disclosure
Investigators and sub-investigators will provide the sponsor with sufficient, accurate financial information as requested to allow the sponsor to submit complete and accurate financial certification or disclosure statements to the appropriate regulatory  authorities. I nvestigators 
are responsible for providing information on financial interests during the course of the stud y 
and for 1 year after completion of the study .
10.1.3 Informed Consent Proce ss
The investigator or his/her representative will explain the nature of the study to the participant or his/her legally  authorized representative and answer all questions 
regarding the stud y. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  56of 78
Participants must be informed that their participation is voluntary . Participants or their 
legally  authorized representative will be required to sign a statement of informed 
consent that meets the requirements of [ADDRESS_1239206] (HIPAA) requirements, where 
applicable, and the IRB/IEC or study  center. 
The medical record must include a statement that written informed consent was 
obtained before the participant was enrolled in the study  and the date the written 
consent was obtained. The au thorized person obtaining the informed consent must also 
sign the ICF.
Participants must be re -consented to the most current version of the ICF(s) during 
their participation in the study . 
A cop y of the ICF(s) must be provided to the participant or the par ticipant’s legall y 
authorized representative. 
If the participant withdraws consent for disclosure of future information, the sponsor 
may retain and continue to use any  data collected before such a withdrawal of consent. 
Pharmacogenetic samples will be ta ken during the study . Study  participants will be 
asked to sign a separate informed consent for pharmacogenetic research. 
10.1.4 Data Protection
Participants will be assigned a unique identifier by  [CONTACT_456]. Any  participant 
records or datasets that are transferred to the sponsor will contain the identifier only; 
participant names or an y information which would make the participant identifiable 
will not be transferred. 
The participant must be informed that his/her personal study -related data will be used 
by [CONTACT_10999]. The level of disclosure 
must also be explained to the participant. 
The participant must be informed that his/her medical records may  be examined by  
[CONTACT_171138], by  [CONTACT_6667]/IEC members, and by  [CONTACT_55894].
10.1.5 Committees Structur e
[IP_ADDRESS] Executive Committee
The Executive Committee, which consists of external experts in the area of neurology  and 
cardiology and will include the Steering Committee heads of the three Phase 2 studies with 
BAY 2433334 , as well as two sponsor representatives, will ensure the overarching integrit y of 
the three Phase 2 studies with BAY 2433334. Details of the committee will be specified in the 
Executive Committee Charter. 
[IP_ADDRESS] Steering Committee (SC)
The main task of the Steering Committee, which is composed of a pane l of experts in the field
of cardiology , is to support the protocol development and the conduct of the study ,to advise 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  57of 78
the sponsor on clinical, medical, and scientific questions, and to support publications . Details 
of the committee will be specified in the Steering Committee charter.
[IP_ADDRESS] Independent Data Monitoring Committee (IDMC)
Ongoing safet y monitoring during the conduct of the study will be performed by [CONTACT_885746]. An independent statistical anal ysis center (SAC) will be involved i n 
processing unblinded safety  data for the IDMC. Analy sis periods and procedures will be 
defined in an operational charter ( IDMC Charter) filed in the study  file. Following data 
review, the IDMC will provide written recommendations that will be transferred to Bay er. All 
other definitions will be provided in the IDMC charter.
[IP_ADDRESS] Clinical Events Committee (CEC)
Potential pre -specified clinical outcome events will be submitted for adjudication to an 
independent CEC. A djudication of all bleeding events as well as efficacy  events will be 
performed b y members of the CEC who will review events in a blinded fashion and will 
adjudicate and classify  the following events in a consistent and unbiased manner according to 
definitions contained in the CEC charter . The adjudic ation will also include algorithm 
approaches :
Bleeding events according to the following classifications:
 ISTH (major, clinicall y relevant non- major and minor)
 TIMI (major, minor, requiring medical attention, minimal)
 BARC (ty pe 1,2,3,5)
Death (CV death [ including death with unknown cause] or non- CV death)
MI
Stroke (ischemic, hemorrhagic, undetermined)
Stent thrombosis
In addition, events that might be indicative of a potential outcome event will be reported as 
outcome events to ensure that no outcome event is missed. This includes for example TIA and hospi[INVESTIGATOR_55849].
Data entry  procedures and documentation necessary  for case adjudication will also be 
described in the CEC charter. Adjudication results will be the basis for the final anal ysis.
10.1.6 Dissemination of Clinical Study Data
Result summaries of Bayer's sponsored clinical studies in drug development Phases 2, 3 and 4 
and Phase 1 studies in patients are provided in the Bay er Trial Finder application after 
marketing authorization approval in line with the position of the global pharmaceutical industry  assoc iations laid down in the "Joint Position on the Disclosure of Clinical Trial 
Information via Clinical Trial Registries and Databases". In addition, results of clinical drug  
trials will be provided on the publicly  funded website www.ClinicalTrials.gov and EU 
Clinical Trials Register in line with the applicable regulations. 
Bayer commits to sharing upon request from qualified scientific and medical researchers 
patient -level clinical trial data, study -level clinical trial data, and protocols from clinical t rials 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  58of 78
in patients for medicines and indications approved in the [LOCATION_002] (US) and European 
Union (EU) on or after January  01, 2014 as necessary  for conducting legitimate research. 
All Bay er-sponsored clinical trials are considered for publication in the scientific literature 
irrespective of whether the results of the clinical studies are positive or negative.
10.1.7 Data Quality Assurance
All participant data relating to the study will be recorded on printed or electronic CRF 
unless transmitted to the sponsor or designee electronically  (eg, laboratory  data). The 
investigator is responsible for verify ing that data entries are accurate and correct by  
[CONTACT_55896] y or electronically signing the CRF. 
The investigator must maintain accurate documentation (source dat a) that supports the 
information entered in the CRF. 
The investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory  agency  inspections and provide direct access to source data documents. 
Monitoring details describing strate gy (eg, risk- based initiatives in operations and 
quality  such as Risk Management and Mitigation Strategies and Anal ytical Risk -
Based Monitoring), methods, responsibilities and requirements, including handling of 
noncompliance issues and monitoring techniqu es (central, remote, or on -site 
monitoring) are provided in the Monitoring Plan.
The sponsor or designee is responsible for the data management of this study  
including qualit y checking of the data. 
The sponsor assumes accountability for actions delegated to other individuals (e.g., 
Contract Research Organizations).
Study  monitors will perform ongoing source data verification to confirm that data 
entered into the CRF b y authorized site personnel are accurate, complete, and 
verifiable from source documents; that the safet y and rights of participants are being 
protected; and that the study  is being conducted in accordance with the currentl y 
approved protocol and any other stud y agreements, I CH GCP, and all applicable 
regulatory  requirements. 
Records and documents, including signed ICFs, pertaining to the conduct of this study  
must be retained b y the investigator for 15years after study  completion unless local 
regulations or institutional policies require a longer retention period. No records may  
be destro yed d uring the retention period without the written approval of the sponsor. 
No records may  be transferred to another location or part y without written notification 
to the sponsor. 
If the participant withdraw consent for disclosure of future information, the s ponsor 
may retain and continue to use any  data collected before such a withdrawal of consent.
[IP_ADDRESS] Data Recording
The data collection tool for this study  will be a validated electronic data capture sy stem called 
RAVE. Participant data necessary  for anal ysis and reporting will be entered/transmitted into a 
validated database or data sy stem (L SH).
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  59of [ADDRESS_1239207] facility  maintained by  [CONTACT_885747] a 
periodic basis to Bay er's internal computer s ystem via a secure Virtual Private Network.
All access to the RAVE system is through a password- protected security  system that is part of 
the RAVE software. All internal Bay er and external investigator site personnel seeking access 
must go through a thorough RAVE training process before they  are granted access to RAVE 
for use in Bay er's clinical studies. Training records are maintained.
All personnel with access to the RAVE sy stem are supported by  a Service Desk staffed with 
trained personnel to answer questions and ensure access is maintained such that data entry  can 
proceed in a timely  manner.
The RAVE Sy stem contains a sy stem -generated audit trail that captures any changes made to 
a data field, including who made the change, wh y the change was made and the date and time 
it was made. This information is available both at the inve stigator’s site and at Bay er. Data 
entries made in the RAVE EDC screens are supported by [CONTACT_885748] s enrolled in this study .
Data recorded from screening failures
At minimum, the following data should be recorded in the CRF:
Demographic information ( participant number; year of birth /age; sex; if applicable 
race / ethnicity )
Date of informed consent
Relevant inclusion/exclusion criteria
Reason for premature discontinuation
Date of last visit.
These data will be transferred to the respective database.
[IP_ADDRESS] Monitoring
In accordance with applicable regulations, ICH-GCP, and sponsor’s/CRO’s procedures, 
monitors will contact [CONTACT_885749], study  requirem ents, and their responsibilities to satisfy  regulatory, ethical, and 
sponsor’s requirements. When reviewing data collection procedures, the discussion will also 
include identification and documentation of source data items.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  60of 78
Thesponsor /designee will monito r the site activity  to verify  that the:
Data are authentic, accurate and complete.
Supporting data may  be requested (example: blood glucose readings to support a 
diagnosis of diabetes). 
Safety  and rights of participant s are being protected
Study  is conduc ted in accordance with the currently  approved protocol
(including stud y treatment being used in accordance with the protocol)
Any other study  agreements, ICH-GCP, and all applicable regulatory  requirements are 
met.
The investigator and the head of the medical institution (where applicable) agrees to allow the monitor direct access to all relevant documents.
[IP_ADDRESS] Data processing
Data will be collected as described in Section [IP_ADDRESS] . Clinical data management will be 
performed in accordance with applicable sponsor’s/CRO’s standards and data cleaning procedures. This is applicable for data recorded on eCRF as well as for data from othe r 
sources (e.g. I xRS, laboratory , adjudication committees).
For data coding (e.g. AEs, medication), internationally  recognized and accepted dictionaries 
will be used.
After its initial release for biometrical anal ysis, additional data release for analy sis is possible, 
to include, for example, the following data: pharmacokinetic data, pharmacody namic data, 
anti-drug antibod y data etc.
[IP_ADDRESS] Missing data
All efforts will be made to collect complete data for all participant s randomized in this study . 
Participants wi ll be followed up to the study  end and all required data will be collected, 
regardless of participant s’ compliance with stud y drug use or the visit schedule. 
Data from participant s who prematurel y terminate the study  will be used to the maximum 
extent possible. All missing or partial data will be presented in the participant data listing as 
they are recorded in the eCRF. Data are collected primarily  through an EDC sy stem, which 
allows ongoing data entry and monitoring.
[IP_ADDRESS] Audit and inspection
To ensure compli ance with ICH-GCP and regulatory  requirements, a member of the sponsor’s 
(or a designated CRO’s) quality  assurance unit may  arrange to conduct an audit to assess the 
performance of the study at the study  site and of the study  documents originating there. T he 
investigator/institution will be informed of the audit outcome.In addition, inspections by [CONTACT_8993](s)/I RB(s) are 
possible. The investigator should notify  the sponsor immediately  of any  such inspection.
The investigator/institution agrees to allow the auditor or inspector direct access to all relevant 
documents and allocate his/her time and the time of his/her staff to the auditor/inspector to 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  61of 78
discuss findings and an y issues. Audits and inspections may  occur at an y time during or after 
completion of the study .
[IP_ADDRESS] Archiving
Essential documents shall be archived safel y and securel y in such a way that ensures that they  
are readil y available upon authorities’ request.
Participant (hospi[INVESTIGATOR_307]) files will be archived according to local regulations and in accordance 
with the maximum period of time permitted by  [CONTACT_5035][INVESTIGATOR_307], institution or private practice. 
Where the archiving procedures do not meet the minimum timelines required by  [CONTACT_177262], 
alternative arrangements must be made to ensure the availability  of the source documents for 
the required period.
The investigator/institution notifies the sponsor if the archival arrangements change 
(e.g. relocation or transfer of ownership).
The investigator site file is not to be destroyed without the sponsor’s approval.
The contract with the investigator/institution will contain all regulations relevant for the stud y 
site.
10.1.8 Source Documents
Source documents provide evidence for the existence of the participant and substantiate the integrity  of the data collected. Source documents are filed at the 
investigator’s site.
Data reported on the CRF or entered in the eCRF that are transcribed from source 
documents must be consistent with the source docu ments or the discrepancies must be 
explained. The investigator may need to request previous medical records or transfer 
records, depending on the study . Also, current medical records must be available.
Definition of what constitutes source data can be foun d in the source data 
identification checklist
The site must implement processes to ensure availability  of all required source 
documentation (e.g. participant file, local laboratory  report, etc.). A source document 
checklist (not part of this protocol) will be used at the site to identify  the source data 
for key  data points collected and the monitor will work with the site to complete this.
Race and ethnic group may  be entered directly  into the CRF, without availability  of 
corresponding source documentation. Thus, these CRF data will be the source and no additional source documentation will be available. For all other data, source documentation must be available at the site.
10.1.[ADDRESS_1239208] been collected and a study -site closure visit has been performed.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  62of 78
The investigator may  initiate study -site closure at any  time, provided there is reasonable cause 
and sufficient notice is given in advance of the intended termination.
Reasons for the earl y closure of a stud ysite by  [CONTACT_17095]:
Failure of the investigator to comply  with the protocol, the requirements of the 
IRB/IEC or local health authorities, the sponsor's procedures, or GCP guidelines
Inadequate recruitmen t of participants by  [CONTACT_093]
Discontinuation of further study  intervention development
If the stud y is prematurely terminated or suspended, the sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory  authorities, and any  contract research 
organization(s) used in the study  of the reason for termination or suspension, as specified b y 
the applicable regulatory  requirements. The Investigator shall promptly  inform the participant
and should assure appropriate participant therapy  and/or follow -up.
10.1.10 Publication Policy
The results of this study  may  be published or presented at s cientific meetings. If this is 
foreseen, the investigator agrees to submit all manuscripts or abstracts to the sponsor 
before submission. This allows the sponsor to protect proprietary  information and to 
provide comments. 
The sponsor will comply  with the requirements for publication of study  results. I n 
accordance with standard editorial and ethical practice, the sponsor will generall y 
support publication of multicenter studies only in their entiret y and not as individual 
site data. In this case, a coordin ating investigator will be designated b y mutual 
agreement.
Authorship will be determined by  [CONTACT_11403] I nternational 
Committee of Medical Journal Editors authorship requirements.
10.2 Appendix 2: Clinical Laboratory Tests
The tests detailed in Table 10–1 will be performed by  [CONTACT_2237] .
Protocol -specific requirements for inclusion or exclusion of participants are detailed i n 
Section 5 of the protocol.
Additional tests may  be performed at an y time during the study as determined 
necessary  by [CONTACT_633405].
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  63of 78
Table 10–1 : Protocol -Required Safety Laboratory Assessments
Laboratory 
AssessmentsParameters
Hematology Platelet c ount RBC Indices:
MCV
MCH%Reticuloc ytesWhite blood cell (W BC) 
count with Differential:
NeutrophilsLymphocytes
Monoc ytes
EosinophilsBasophilsRed blood cell (RBC) count
Hemoglobin
Hematocrit
Clinical Chemistry1Aspartate Aminotransferase (AST)         
Alanine Aminotransferase (ALT)Alkaline phosphatase (AP)Gamma glutam yl transpeptidase ( γGT)
Bilirubin, total and direct
Lactate dehydrogenase (LDH)
Creatinine kinase (CK)
Blood Urea Nitrogen (BUN)CreatinineeGFR
LipaseAmylase
SodiumPotassium
Calcium
Uric acid
GlucoseCholesterol (total, HDL, LDL)TriglyceridesAlbuminTotal protein
Thyroid-stimulating hormone (TSH)
NOTES:
1 Details of liver chemistry  stoppi[INVESTIGATOR_21357] -up assessments after liver 
stoppi[INVESTIGATOR_31777] 7.1and Appendix 10.5 .
Abbreviations: ALT = alanine aminotransferase, AP = alkaline phosphatase, AST =aspartate 
aminotransferase, BUN = blood urea nitrogen, CK = creatinine kinase, eGFR =estimated glomerular fil tration 
rate, γGT =gamma glutamyl transpeptidase, HDL =high-density lipoprotein, LDH = lactate dehydrogenase, 
LDL =low-density lipoprotein, MCH = mean corpuscular hemoglobin, MCV = mean corpuscular volume, 
RBC =red blood cell (count), TSH =thyroid -stimulating hormone, W BC=white blood cell (count)
Investigator must document their review of each laboratory  safet y report.
The name [CONTACT_55912]  [CONTACT_55899]. In the eve nt of implausible results, the laboratory  may  
measure additional parameters to assess the quality of the sample (e.g. clotted or hemoly zed) 
and to verify  the results. The results from such additional analy ses may  neither be included in 
the clinical databas e of this study  nor evaluated further. If the results are relevant, the 
investigator will be informed to determine follow-up activities outside of this protocol. 
All exploratory  biomarkers are not used routinely  in practice and will be analy zed in batches. 
Therefore, timel y reporting of the results will not be possible during the study and review of 
the results will not assist participant care.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  64of 78
10.3 Appendix 3: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting
10.3.1 Definition of AE 
AE Definition
An AE is an y untoward medical occurrence in a patient or clinical study participant, 
associated with the use of study  intervention, whether or not considered related to 
the study  intervention.
NOTE: An AE can therefore be an y unfavorable and unintended sign (including an 
abnormal laboratory  finding), s ymptom, or disease (new or exacerbated) associated 
with the use of study  intervention.
Events Meeting the AE Definition 
Any abnormal laboratory test results (hematology , clinical chemistry , or urinaly sis) 
or other safet y assessments (eg, ECG, radiological scans, vital signs measurements), 
including those that worsen from baseline, considered clinicall y significant in the 
medical and scientific judgment of the investigator.
Exacerbation of a chronic or intermittent pre-existing condition including either an 
increase in frequency  and/or intensity  of the condition.
New conditions detected or diagnosed after stud y intervention administration even 
though it may  have been present before the start of the study .
Signs, sy mptoms, or the clinical sequelae of a suspected drug -drug interaction.
Signs, sy mptoms, or the clinical sequelae of a suspected overdose of either study  
intervention or a concomitant medication. Overdose per se will not be reported as an 
AE/SAE unless it is an intentional overdose taken with possible suicidal/self -
harming intent. Such overdoses should be reported regardless of sequelae.
Thesigns, s ymptoms, and/or clinical sequelae resulting from lack of efficacy  will be 
reported as AE or SAE if they  fulfil the definition of an AE or SAE. Also, “lack of 
efficacy ” or “failure of expected pharmacological action” also constitutes an AE or 
SAE.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  65of 78
Events NOT Meeting the AE Definition 
Any clinically  significant abnormal laboratory  findings or other abnormal safet y 
assessments which are associated with the underl ying disease, unless judged by  [CONTACT_11009]’s condition.
The disease/disorder being studied or expected pro gression, signs, or s ymptoms of 
the disease/disorder being studied, unless more severe than expected for the 
participant’s condition.
Medical or surgical procedure (eg, endoscop y, appendectom y): the condition that 
leads to the procedure is the AE.
Situatio ns in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Anticipated day -to-day fluctuations of pre -existing disease(s) or condition(s) present 
or detected at the start of the study that do not worsen.
10.3.2 Definition of SAE
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (e.g., hospi[INVESTIGATOR_1080]/sy mptoms of the disease under study , death 
due to progression of disease).
AnSAE is defined as any untoward medical occurrence that, at any dose:
a. Results in death
b. Is life -threatening
The term 'life -threatening' in the definition of 'serious' refers to an event in which the 
participant was at risk of death at the time of the event . It does not refer to an event, 
which hy potheticall y might have caused death, if it were more severe.
c. Requires inpatient hospi[INVESTIGATOR_1081]
In general, hospi[INVESTIGATOR_885736] (usually  
involving at least an overnight stay ) at the hospi[INVESTIGATOR_23917]/or treatment that would not have been appropriate in the phy sician’s 
office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_059] a re AEs. 
If a complication prolongs hospi[INVESTIGATOR_23919], the 
event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary , the AE should be considered serious.
Hospi[INVESTIGATOR_5187] a pre -existing condition that did not worsen 
from baseline is not considered an AE.
d. Results in persistent disability/incapacity
The term disability means a substantial disruption of a person’s ability  to conduct 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  66of 78
normal life functions.
This definition is not intended to include experiences of relativel y minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, 
and accidental trauma (eg, sprained ankle) which may  interfere with or prevent 
every day life functions but do not constitute a substantial disruption.
e. Is a congenital anomaly/birth defect
f. Other situations:
Medical or scientific judgment should be exercised in deciding whether SAE 
reporting is appropriate in other situations such as importa nt medical events that 
may not be immediatel y life-threatening or result in death or hospi[INVESTIGATOR_268678]. These events should usually  
be considered serious.
Examples of such events include invasive or malignant cancers, intensive treatment 
in an emergency  room or at home for allergic bronchospasm, blood dy scrasias or 
convulsions that do not result in hospi[INVESTIGATOR_3094], or development of drug dependency 
or drug abuse.
10.3.3 Recording and Follow -Up of AE and/or SAE 
AE and SAE Recording
When an AE/SAE occurs, it is the responsibility  of the investigator to review all 
documentation (e .g., hospi[INVESTIGATOR_1088], laboratory  reports, and diagnostics 
reports) related to the event.
The investigator will then record all relevant AE/SAE information in the CRF.
It is not acceptable for the investigator to send photocopi[INVESTIGATOR_10914]’s medical records to the sponsor in lieu of completion of the AE/SAE CRF page.
There may  be instances when copi[INVESTIGATOR_19952] b y the sponsor . In this case, all participant identifiers, with the exception 
of the participant number, will be redacted on the copi[INVESTIGATOR_55852].
The investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not 
the individual si gns/sy mptoms) will be documented as the AE/SAE.
Assessment of Intensity
The investigator will make an assessment of intensity for each AE and SAE reported 
during the stud y and assign it to 1 of the following categories: 
Mild: An event that is easily  tolerated by  [CONTACT_2299], causing minimal 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  67of 78
discomfort and not interfering with every day activities.
Moderate: An event that causes sufficient discomfort and interferes with normal 
every day activities.
Severe: An event that prevents normal every day activities. An AE that is 
assessed as severe should not be confused wit h an SAE. Se vere is a category 
utilized for rating the intensity  of an event; and both AEs and SAEs can be 
assessed as severe.
An event is defined as ‘serious’ when it meets at least 1 of the predefined outcomes as described in the definition of an SAE, NOT when it is rated as severe.
Assessment of Causality
The investigator is obligated to assess the relationship between stud y intervention 
and each occurrence of each AE/SAE.
A “reasonable possibility” of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rather than a relationship cannot 
be ruled out.
The investigator will use clinical judgment t o determine the relationship.
Alternative causes, such as underl ying disease(s), concomitant therap y, and other 
risk factors, as well as the temporal relationship of the event to study  intervention 
administration will be considered and investigated.
The investigator will also consult the Investigator’s Brochure (IB) and/or Product 
Information, for marketed products, in his/her assessment.
For each AE/SAE, the investigator must document in the medical notes that he/she 
has reviewed the AE/SAE and has provide d an assessment of causality .
There may  be situations in which an SAE has occurred and the investigator has 
minimal information to include in the initial report to the sponsor . However, it is 
very important that the investigator always make an assessment o f causality for 
every event before the initial transmission of the SAE data to [ the sponsor.
The investigator may  change his/her opi[INVESTIGATOR_19954] -up 
information and send a nSAE follow -up report with the updated causality  
assessment.
The causality  assessment is one of the criteria used when determining regulatory  
reporting requirements.
Follow -up of AEs and SAEs
The investigator is obligated to perform or arrange for the conduct of supplemental measurements and/or evaluations as medically  indicated or as requested by  [CONTACT_55900]/or causalit y of the AE or SAE as fully as 
possible. This may  include additional laboratory  tests or investigations, 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  68of 78
histopathological examinations, or consultation with other health care professionals.
If a participant dies during participation in the study  or during a recognized follow -
up period, the investigator will provide  with a copy  
of an y post mortem findings including histopathology.
New or updated information will be recorded in the originally completed CRF.
The investigator will submit any  updated SAE data to the [sponsor] within 24 hours 
of receipt of the information.
10.3.4 Reporting of SAEs
SAE Reporting to the sponsor via an Electronic Data Collection Tool
The primary  mechanism for reporting an SAE to the sponsor will be the electronic 
data collection tool.
If the electronic s ystem is unavailable, then the site will use the paper SAE data 
collection tool (see next section) in order to report the event within 24 hours
The site will enter the SAE data into the electronic sy stem as soon as it becomes 
available.
After the stud y is completed at a given site, the electronic data collection tool will be 
taken off -line to prevent the entry  of new data or changes to existing data.
If a site receives a report of a new SAE from a study  participant or receives updated 
data on a previously  reported SAE after the electronic data collection tool has been 
taken off -line, then the site can report this information on a paper SA E form and 
transmit to  
Contacts for SAE reporting can be found in the Investigator Site File .
SAE Reporting to the sponsor via Paper CRF
Facsimile transmission of the SAE paper CRF is the preferred method to transmit 
this information to the Sponsor via 
In rare circumstances and in the absence of facsimile equipment, notification by  
[CONTACT_9337] a cop y of the SAE data collection tool sent by  [CONTACT_19515].
Initial notification via telephone does not replace the need for the investigator to 
complete and sign the SAE CRF pages within the designated reporting time frames.
Contacts for SAE r eporting can be found in the Investigator Site File.
[COMPANY_003]
[COMPANY_003]
[COMPANY_003]
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  69of 78
10.3.5 Outcome Event Reporting Process Overview
If an AE or SAE is a potential outcome event (all bleeding, death, MI, str oke, TIA and stent 
thrombosis [Section 8.3.6] ), itmust be collected and reported on the dedicated forms on an 
ongoing basis, until the participant has completed the study. Thus , even if a participant is no 
longer taking stud y medication this would be until the end of the regular, planned end of 
treatment for this participant ( i.e. until the participant’s last visit . After completion of safet y 
follow -up visit, for participants that prematurel y discontinued study intervention, there is no 
further requirement for reporting AEs. Onl y potential outcome events are to be reported (refer 
to section 8.3.1 and10.8).
10.4 Appendix 4: Contraceptive Guidance and Collection of Pregnancy 
Information
Definitions:
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post -menopausal 
unless permanentl y sterile (see below).
If fertility  is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cy cle cannot 
be confirmed before first dose of study intervention, additional evaluation should be 
considered.
Women in the foll owing categories are not considered WOCBP
1.Premenarchal
2.Premenopausal female with 1 of the following:
Documented h ysterectomy
Documented bilateral salpi[INVESTIGATOR_1656]
Documented bilateral oophorectom y
For individuals with permanent infertility due to an alt ernate medical cause other than the 
above, (eg, Müllerian agenesis, androgen insensitivity ), investigator discretion should be 
applied to determining study  entry .
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview.
Postmenopausal Female
A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. 
A high follicle stimulating hormone (FSH) level in the postmenopausal range may  be 
used to confirm a postmenopausal state in women not using hormonal contraception or hormonal replacement therap y (HRT). However, in the absence of 12 months of 
amenorrhea, c onfirmation with more than one FSH measurement (>40 IU/L) is 
required. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  70of 78
Females on HRT and whose menopausal status is in doubt will be required to use one 
of the non-estrogen hormonal highl y effective contraception methods if they wish to 
continue their HR T during the study. Otherwise, they  must discontinue HRT to allow 
confirmation of postmenopausal status before study  enrollment.
Contraception Guidance:
Female participants must be of non -child bearing potential as per Clinical Trial 
Facilitation Group (C TFG) guidelines.
Male participants must agree to use condoms when sexually  active with a woman of 
childbearing potential from the time of the first dose to [ADDRESS_1239209] dose of 
study  intervention .This is in line with the CTFG guideline, as BAY 2433334 is non 
genotoxic but data related to teratogenicit y/fetotoxicity  in early  pregnancy  (Segment 2 
studies) are not available at this stage of development. I n addition, all men must not 
donate sperm duri ng the study .
Male Participants with Partners Who Become Pregnant 
The investigator will attempt to collect pregnancy  information on any  male 
participant’s female partner who becomes pregnant while the male participant is in 
this study . This applies only  to male participants who receive stud y intervention.
After obtaining the necessary  signed informed consent from the pregnant female 
partner directl y, the investigator will record pregnancy information on the appropriate 
form and submit it to the sponsor within 24 hours of learning of the partner’s pregnancy . The female partner will also be followed to determine the outcome of the 
pregnancy . Information on the status of the mother and child will be forwarded to the 
sponsor. Generally , the follow -up will be no longer than 6 to 8 weeks following the 
estimated delivery  date. Any  termination of the pregnancy  will be reported regardless 
of fetal status (presence or absence of anomalies) or indication for the procedure.
Female p articipants W ho Become Pregnant 
The investigator will collect pregnancy  information on any  female participant who 
becomes pregnant while participating in this study. I nformation will be recorded on 
the appropriate form and submitted to the sponsor within 24 hours of learning of a 
partici pant's pregnancy . 
The participant will be followed to determine the outcome of the pregnancy . The 
investigator will collect follow -up information on the participant and the neonate , after 
obtaining the signed informed consent from both parents, unless loc al law or specific 
circumstances of the respective case allow otherwise, and the information will be forwarded to the sponsor. Generally , follow -up will not be required for longer than 6 
to 8 weeks bey ond the estimated delivery  date. Any  termination of pre gnancy  will be 
reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure.
While pregnancy  itself is not considered to be an AE or SAE, any  pregnancy  
complication or elective termination of a pregnancy will be r eported for medical 
reasons will be reported as an AE or SAE. 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  71of 78
A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth
(occurring at >22 weeks gestional age) is alway s considered to be an SAE and will be 
reported as such. 
Any post -study  pregnancy  related SAE considered reasonably related to the study  
intervention by  [CONTACT_55901] 
8.3.4. While the investigator is not obligated to actively  seek this information in 
former stud y participants, he or she may learn of an SAE through spontaneous 
reporting. 
Any female participant who becomes pregnant while participating in the study  will be 
withdrawn from the study .
10.5 Appendix 5: Liver Safety: Suggested Actions and Follow -up Assessments 
Any participant with an AL T or AST > [ADDRESS_1239210] bilirubin,  AP and INR , and will be assessed b y local laboratory. There 
also should be inquiry  made about s ymptoms.
Every  effort should be made to clarify  the etiology  of elevated levels and lab testing may  
include, but not be limited to, testing for viral hepatitis, cy tomegalovirus, Epstein -Barr virus, 
human immunodeficiency virus (once the participant has provided written consent), testing of 
ferritin levels, iron, iron binding capacit y, antinuclear antibod y, and smooth muscle 
antibodies. Patient management is at the discretion of the treating ph ysician but the 
investigator  may  continue the study  drug during retesting .
Liver function test monitoring should be performed as above for all participants with elevated 
ALT or AST >[ADDRESS_1239211] 
normalized or returned to patient’s baseline. If close liver monitoring is n ot possible then the 
patient should discontinue study  medication.
For ALT or AST >  [ADDRESS_1239212] concurrent with a total bilirubin > [ADDRESS_1239213], every  effort should 
be made to promptly  clarify  any possible underl ying disease(s).
The frequency  of liver function test s based on re -test values is shown in Table 10–2. 
Table 10–[ADDRESS_1239214] >  [ADDRESS_1239215] ≤ [ADDRESS_1239216] Once a week Until return to normal or patient baseline levels
ALT = alanine aminotransferase; AST = aspartate aminotransferase; ULN = upper limit of normal
Discontinuation of treatment should be considered if: 
ALT or AST >  [ADDRESS_1239217] 
ALT or AST >  [ADDRESS_1239218] for more than 2 weeks 
ALT or AST >  [ADDRESS_1239219] and(total bilirubin >  [ADDRESS_1239220] or INR >  1.5) 
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  72of 78
ALT or AST >  [ADDRESS_1239221] with the appearance of fatigue, nausea, vomiting, right upper 
quadrant pain or tenderness, fever, rash, and /  or eosinophilia (>  5%) 
10.6 Appendix 6: Calculating the Child -Pugh score
The severit y of liver disease ( Table 10–3) will determine the Child -Pugh score ( Table 10–4).
Table 10–3 Grading of severity of liver disease 
Factor +1 +2 +3
Bilirubin (mg/dL) < 2 2 – 3 > 3
Albumin (g/dL) > 3.5 2.8 –3.5 < 2.8
International Normalized Ratio < 1.7 1.7 –2.3 > 2.3
Ascites None Mild Moderate  / Severe
Encephalopathy None Grade I -II Grade III –IV
Source: adapted from (Pugh et al. 1973 )
Table 10–4 Child -Pugh score 
Child -Pugh Class A B C
Points 5 6 7 – 9 10 15
Source: adapted from (Pugh et al. 1973 )
10.7 Appendix 7: Calculating glomerular filtration rate
In accordance with established nephrology  practice and guidelines, renal function at baseline 
and throughout the study  will be assessed by  [CONTACT_55902] 
(eGFR), calculated using the Modification of Diet in Renal Disease (MDRD) study  
abbreviated formula.
Isotope dilution mass spectroscopy (IDMS)- traceable MDRD Study E quation:
Conventional units (serum creatinine level is measured in mg/dL)
GFR (mL/min/1.73 m2) = 175 x (serum creatinine)-1.154x (Age)-0.203x (0.742 if female) x 
(1.212 if African American)GFR can be estimated using the calculator provided in the following link: http://www.kidney .org/professionals/kdoqi/gfr_calculator .
For further information on assessing renal function using GFR estimates (Levey  et al. 2006 )
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  73of 78
10.8 Appendix 8: Outcome Events: Data Collection
All outcome events (efficacy  and safet y) are to be captured and reported from randomization 
until participant´s regular last scheduled study  visits (ie, Safet y Follow -up Visit; in case of 
permanent discontinuation of study  intervention , the planned regular EoT visit). The eCRF
will contain specific Outcome Event pages, as well as AEs subpages to capture the outcome 
events oc curring throughout the study . The following points need to be considered when 
reporting outcome events.
Outcomes events occurring after randomization and before the first intake of the study
intervention : the outcome event will be considered part of the me dical history  and should 
be reported in the outcome event eCRF page 
Outcomes events occurring after randomization and after first intake of study 
intervention and up to the SFU visit : the outcome event will be considered both AE and 
outcome event and shou ld be reported in both in the AE page and in the AE’ s subpage for 
outcome events.
Outcome events occurring after SFU visit through the end of the study (for participant 
who discontinue study intervention): the outcome events should be collected until 
completion of participant´s regular scheduled study  visits and should be reported in the 
outcome event eCRF page.
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  74of 78
10.9 Appendix 9: Abbreviations
ACC American College of Cardiology
ACS Acute coronary  syndrome
AE Adverse Event
AESI Adverse event of special interest
AF Atrial fibrillation
AG Joint stock company , Aktiengesellschaft
AHA American Heart Association
ALT Alanine aminotransferase
AMI Acute m yocardial infarction
AP Alkaline phosphatase
aPTT Activated partial thromboplastin time       
ARC Academic Research Consortium
ASA Acet ylsalicy lic acid
ASO Antisense oligonucleotide
AST Aspartate Aminotransferase
AUC Area under the curve
AXIA Activated Factor XIa activity
AxMP Auxiliary  medicinal product
BARC Bleeding Academic Research Consortium
BID Twice a day ,Bis in die
BL Baseline
BP Blood pressure
BUN Blood urea nitrogen
CABG Coronary  artery  by[CONTACT_885750]/F Apparent oral plasma clearance
Cmax maximum observed concentration reached after administration
CONSORT Consolidated Standards of Reporting Trials
CRF Case report form
CSR Clinical study  report
CTFG Clinical Trial Facilitation Group
CRNM Clinical relevant non -major
CRO Contract Research Organization
CV Cardiovascular 
CYP3A4 Cytochrome P450, family  3, subfamily  A, pol ypeptide 4
DAPT Dual antiplatelet therap y
e.g. For example, exempli gratia
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  75of [ADDRESS_1239222]
IB Investigator’s brochure
ICF Informed consent form
ICH International Council for Harmonization
IDMC Independent data monitoring commitee
IDMS Isotope dilution mass spectroscop y
IEC Independent Ethics Committee
IMP Investigational medical product
IND Investigational New Drug
INN International non -proprietary  name
[CONTACT_885751]. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  76of [ADDRESS_1239223]
ISTH International Societ y on Thrombosis and Hemostasis 
ITT Intent -to-treat
IV Intravenous(l y)
IVRS/I WRS, IxRS Interactive Voice/Web Response Sy stem
LDH Lactate deh ydrogenase
LDL Low-densit y lipoprotein
LSF Liquid service formulation
MCH Mean corpuscular hemoglobin
MCV Mean corpuscular volume
MD/ MDE Multiple dose / multiple dose escalation
MDRD Modification of Diet in Renal Disease
MedDRA Medical Dictionary  for Regulatory  Activities
MI Myocardial infarction
MRI Magnetic resonance imaging
N Total number of participants
NA Not applicable
NIHSS National Institutes of Health Stroke Scale
NJ New Jersey
NOAC Non-Vitamin K oral anticoagulant
NSAID Nonsteroidal anti -inflammatory  drug
NT-proBNP N-terminal pro B -type Natriuretic Peptide
OD Once dail y
P2Y 12 Purinergic receptor P2Y, G- protein coupled, 12
PAD Peripheral artery  disease
PCI Percutaneous coronary  intervention
PD Pharmacod ynamic
PK Pharmacokinetic(s)
QC Quality  control
RAAUC Accumulation ratio forAUC
RACmax Accumulation ratio forCmax
RAVE Data collection tool
RBC Red blood cell
RND Randomization
SAC Statictical analy sis center
SAE Serious Adverse Event
SAP Statistical analy sis plan
SAS Statistical analy sis software
SC Steering Committee
SCR Screening
SD Single dose
SFU Safety follow -up
SMOL Small molecule
SoA Schedule of activities
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  77of [ADDRESS_1239224] Upper limit of normal
US/[LOCATION_003] [LOCATION_002]/[LOCATION_002] of America
VKA Vitamin K antagonist
VTE Venous thromoembolism
vWF Von Willebrand Factor
W Week
WBC White blood ce ll
WOCBP Woman of childrenbearing potential
CONFIDENTIAL Clinical Study  Protocol
No. BAY 2433334 / [ZIP_CODE]
Version 1.0                                                                      Page:  78of 78
11. References
AHA/ACC. 2014 AHA/ACC Guideline for the Management of Patients with Non- ST-
Elevation Acute Coronary  Syndromes: Executive Summary . 2014.
Chen Z, Seiffert D, Hawes B. Inhibition of Factor XI activity  as a promising antithrombotic 
strategy . Drug Discov Today . 2014 Sep;19(9):1435-9.
Chesebro JH, Knatterud G, Roberts R, Borer J, Cohen L S, Dalen J, et al. Thromboly sis in 
Myocardial Infarction (TIM I) Trial, Phase I: A comparison between intravenous tissue 
plasminogen activator and intravenous streptokinase. Clinical findings through 
hospi[INVESTIGATOR_2345]. Circulation. 1987 Jul;76(1):142-54.
Duga S, Salomon O. Congenital factor XI deficiency : an update. Semin Thromb Hemost. 
2013 Sep;39(6):621-31.
Garcia -Garcia HM, McFadden EP, Farb A, Mehran R, Stone GW, Spertus J, et al. 
Standardized End Point Definitions for Coronary  Intervention Trials: The Academic 
Research Consortium -2 Consensus Document. Eur Heart J. 2018 Jun 14;39(23):2192 -
207.
Kaatz S, Ahmad D, Spy ropoulos AC, Schulman S, Subcommittee on Control of A. Definition 
of clinically  relevant non- major bleeding in studies of anticoagulants in atrial 
fibrillation and venous thromboembolic disease in non- surgical patients: 
communication from the SSC of the I STH. J Thromb Haemost. 2015 
Nov;13(11):2119-26.
Levey  AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease stud y 
equation for estimating glomerular filtration rate. Ann Intern M ed. 2006 Aug 
15;145(4):247 -54.
Ling G, Kagdi H, Subel B, Chowdary P, Gomez K. Safet y and efficacy of factor XI (FXI) 
concentrate use in patients with FXI deficiency : a single -centre experience of 19 y ears. 
Haemophilia. 2016 May ;22(3):411 -8.
Pugh RN, Murray -Lyon IM, Dawson J L, Pi[INVESTIGATOR_9051], Williams R. Transection of the 
oesophagus for bleeding oesophageal varices. Br J Surg. 1973 Aug;60(8):646 -9.
Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Fourth Universal 
Definition of My ocardial I nfarction (2018). J Am Coll Cardiol. [ADDRESS_1239225] 
30;72(18):[ADDRESS_1239226] on Management of Bleeding in Patients on Oral Anticoagulants : A Report of the American College of Cardiology  Task Force on 
Expert Consensus Decision Pathway s. J Am Coll Cardiol. 2017 Dec 19;70(24):3042 -
67.
Valgimigli M, Bueno H, By [CONTACT_181849], Collet JP, Costa F, Jeppsson A, et al. 2017 ESC focused 
update on dual antiplatelet therap y in coronary artery  disease developed in 
collaboration with EACTS: The Task Force for dual antiplatelet therap y in coronary 
artery  disease of the European Societ y of Cardiology (ESC) and of the European 
Association for Cardio -Thoracic Surgery (EACTS). Eur Heart J. 2018 Jan 
14;39(3):213 -60.